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1.1 BONE BIOLOGY 
The Oxford Dictionary defines bone as “any of the pieces of hard whitish tissue making 
up the skeleton in humans and other vertebrates. The substance of bones is formed by 
specialized cells (osteoblasts) which secrete around themselves a material containing 
calcium salts (which provide hardness and strength in compression) and collagen fibers 
(which provide tensile strength)”. 
More precisely, bone is a dynamic, highly vascular and mineralized connective tissue 
which, together with cartilage, builds up the skeletal system. Its main functions are to 
provide mechanical support, protection of vital organs and a site of muscle attachment 
for locomotion. In addition, bone contains bone marrow and is therefore the primary 
site for the synthesis of blood cells. Furthermore, bone tissue serves as a reserve of 
calcium and phosphate, which is used for the maintenance of serum homeostasis (1).  
Bone consists of approximately 70% inorganic and 30% organic composites. The 
inorganic component contains mainly spindle- or plate-shaped crystals of carbonated 
hydroxyapatite (bone apatite), an insoluble calcium and phosphorus salt that 
precipitates on the protein matrix. This hydroxyl-deficient, but carbonate-rich substance 
is similar to hydroxyapatite but it is not a direct analog (2). 
Only 2% of the organic fraction is made up by cells, growth factors and cytokines, such 
as fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), 
transforming growth factor-beta (TGFβ) and bone morphogenic proteins (BMPs). Ninety 
percent of the so called organic extracellular matrix is formed by collagen type-I fibers. 
Proteoglycans and non-collagenous proteins, as for instance Osteocalcin (OC), 
Osteopontin (= Bone Sialoprotein I, OP), and Bone Sialoprotein II (BSP), account for the 
remaining 8% (1, 3).   
Skeletal elements are initially formed as soft tissue templates. During this process, 
which in humans is completed by the end of the embryonic development, the basic 
shape of all bones is preformed. Thereafter the soft tissue template undergoes gradual 
ossification and growth, leading to an increase in size with relatively little changes in 
shape. This phase of bone formation lasts from the early stages of fetal life until 
adulthood. 
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Two distinct mechanisms are responsible for bone formation: Intramembranous 
ossification, giving rise to flat bones (e.g. scull bones, scapula, mandible and ilium) and 
endochondral ossification, creating long bones (e.g. tibia, femur, humerus and 
vertebrae).  
Both types of ossification involve initial condensation of mesenchyme followed by the 
formation of calcified bone. Whereas intramembranous bone formation accomplishes 
this directly, endochondral ossification involves an intermediate step in which a 
cartilaginous template regulates the growth and patterning of the developing skeletal 
element. Endochondral bone formation initiates with the condensation of loose 
mesenchyme, resulting in the differentiation into cartilage tissue. The cartilaginous 
center subsequently becomes hypertrophic and a center of ossification forms by 
vascular invasion. The secretion and mineralization of extracellular matrix is mediated 
by osteoblasts that are associated with the newly developed vasculature. As bones grow, 
this center of ossification expands and the inside of the shaft region is resorbed (Figure 
1.1) (4, 5). 
Figure 1.1 Intramembranous 
and endochondral ossification. 
While in membranous 
ossification, differentiation of 
mesenchymal cells to 
osteoblasts and bone matrix 
production occur directly, in 
endochondral ossification, 
differentiation to chondrocytes 
and formation of a cartilaginous 
template (anlagen) occurs first, 
followed by replacement of the 
models by bone through 
vascular invasion. (Source (6))  
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The bone surface consists of compact cortical bone (cortex), a thick and dense protective 
layer of calcified tissue which has a high resistance to bending and torsion. It shows an 
increase in thickness in mechanically demanding regions, such as the shafts of long 
bones. The interior of bones, such as within the distal ends of long bones, in short bones, 
in the inner surfaces of flat bones and in irregular bones (e.g. vertebrae), contains thin 
calcified trabeculae, called cancellous or trabecular bone. Spaces enclosed by trabecular 
bone are filled with bone marrow. Due to its more elastic properties, trabecular bone 
contributes to the mechanical support of the skeleton. While cortical bone makes up 
80% of the skeletal mass, trabecular bone represents only 20% of the skeleton by mass, 
but, due to its structure, 80% of the bone surface (3). 
The external surface of all bones is covered with the periosteum, a fibrous membrane 
which contains the blood vessels and nerves that provide nourishment and sensation to 
the bone. It also plays an important role in osteogenesis, as it is colonized by bone cells 
(7). Also the internal bone surface is lined by a thin layer of osteogenic and other cells 
(endosteum). 
In addition to external vascular supply through the peri- and the endosteum, cortical 
bone itself is perfused by blood vessels. These are located in special canals, which also 
accommodate nerves and lymphatic vessels (Haversian canals), and are essential for 
homeostasis of cells embedded within the bone matrix (Figure 1.2).  
Figure 1.2 Schematic drawings of (A) bone tissue and (B) bone blood supply. (Adopted from (8, 9)) 
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Osteoblasts, osteocytes and osteoclasts are the major types of bone cells. Osteoblasts are 
bone forming cells. They originate from local pluripotent mesenchymal stem cells, either 
bone marrow stromal cells residing in the endosteum or connective tissue mesenchymal 
stromal cells from the periosteum. Lining the bone surface, they are gradually trapped in 
the bone matrix which they produce and that calcifies. As a result those cells 
dramatically decrease their metabolic activity, now becoming fully differentiated mature 
bone cells (osteocytes) enclosed in small lacunae. The older they are and the deeper they 
are located within the calcified bone the more they show a decrease in cell volume and 
organelles. Osteocytes are the most abundant cell type in bone tissue. In order to 
communicate with other osteocytes and bone lining cells they extend their cytoplasmic 
processes into the bone matrix and, in this way, constitute a well-developed canalicular 
network. (1, 10).  
In contrast to osteoblasts and osteocytes, osteoclasts are giant multinucleated bone 
resorbing cells, which differentiate from hematopoietic progenitors of the 
monocyte/macrophage lineage. Like osteoblasts they are situated on the bone surface 
(11). The correct interplay between those cell types is essential in bone homeostasis, 
remodeling and repair.  
The process of bone remodeling is a turnover mechanism which permits old bone 
replacement as well as changes in shape, architecture or density of the skeleton. It 
involves three consecutive phases: resorption, during which osteoclasts digest old 
mineralized bone; reversal, when mononuclear cells appear on the bone surface; and 
formation, when osteoblasts lay down new bone until the resorbed bone is completely 
replaced (Figure 1.3) (12). 
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Figure 1.3 Bone remodeling. (A) Bone is formed through the synthesis of bone matrix by osteoblasts 
(formation). As osteoblasts are integrated in the matrix they produce, they become osteocytes or resting 
bone lining cells on the bone surface (quiescence). Due to specific stimulatory factors, preosteoclasts are 
activated to mature to osteoclasts which digest the mineral matrix (resorption). As soon as bone 
resorption finalizes, osteoblasts are recruited and the cycle restarts (reversal). (Source (13)) (B) 
Histologic image of remodeling bone. (Adopted from (14)) 
 
Bone healing is initiated by hematoma formation and inflammation at the fracture site. 
The inflammatory phase is a critical period characterized by low oxygen tension, 
impaired perfusion, and the migration of a wide array of growth factors. Systemwide 
inflammatory conditions also modulate the primary processes of fracture management. 
Osteoprogenitor cells, mesenchymal cells, osteoblasts and chondrocytes contribute to 
the healing and inflammatory response at the bone level. As a second step, bone is 
formed through endochondral or intramembranous ossification very rapidly in a 
provisional manner. During the following remodeling process it is progressively 
replaced by mature bone (15). 
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1.2 BONE DAMAGE AND RECONSTRUCTION 
1.2.1 BONE LOSS AND STANDARD PROCEDURES FOR BONE REPLACEMENT 
As bone remodeling is strictly regulated within a tightly coupled system, any local or 
systemic perturbation leading to uncoupling of the osteoclastic and osteoblastic balance 
may substantially change bone mass. Bone turnover is perturbed in many diseases, each 
characterized by a specific pathophysiology.  
An example for such a metabolic bone diseases is osteoporosis, a chronic progressive 
disorder, in which decreasing bone mass and micro architectural deterioration leads to 
increased bone fragility and fracture risk. Also loss of bone blood supply in 
ostoenecrosis has serious consequences, as it results in death and eventually collapsing 
of bone tissue. External factors well known to cause altered bone turnover are for 
instance use of corticosteroids, immobilization, as well as calcium and vitamin D 
deficiency (3). 
Apart from those degenerative and metabolic forms, bone loss may also be caused by 
trauma. For various reasons, which might be associated with the host, the surgical 
technique, inadequacy of the vasculature and infections, fracture healing can be 
disturbed. In the case of critical-sized bone defects, the osseous damage can be up to 
several centimeters and will not reach complete healing spontaneously (16, 17). 
In contrast to those bone degenerative disorders, bone tumours are characterized by an 
excessive cell growth within the bone which may replace healthy tissue with abnormal 
tissue, thus weakening the bone and causing it to break. Often the tumours need to be 
removed. 
In order to replace bone two different sources are currently used in the clinics. Bone 
taken from the iliac crest, the distal radius, the tibia or the fibula allows autologous 
transfer, but is limited by the amount of tissue that can be removed and the high donor-
site morbidity. Acellular allografts and synthetic bone substitutes do not show these 
disadvantages, but, on the other hand, do not posses the same physiological properties 
as natural bone.  
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Several different approaches to improve therapeutic options, including the refinement of 
synthetic bone grafts or tissue engineering, are at present under investigation. 
 
1.2.2 BONE TISSUE ENGINEERING 
As defined by Langer and Vacanti, “tissue engineering is an interdisciplinary field of 
research that applies the principles of engineering and the life sciences towards the 
development of biological substitutes that restore, maintain, or improve tissue function” 
(18). There are three main approaches to engineer biological bone grafts: (i) to use 
isolated cells, (ii) to use acellular, three-dimensional biomaterials capable of inducing 
tissue regeneration, and (iii) to use a combination of cells and materials (typically in the 
form of scaffolds) (Figure 1.4) (19). In practice, this comprises the following main areas: 
 
1) Matrices: including biomaterials that are designed to direct the organization, growth, 
and differentiation of cells in the process of forming functional bone tissue by providing 
both physical and chemical cues. A large number of various materials are currently 
under investigation or commercially available. The ideal scaffold should be: 
osteoconductive (bone growth on the surface), osteoinductive (induction of 
osteogenesis), biocompatible, bio-resorbable and have similar strength as well as, at the 
same time, a similar modulus of elasticity to that of bone. In addition, it should be easy to 
use and cost-effective. Osteoinductive scaffolds can be devided in natural biomaterials, 
like demineralised bone matrix or collagen based matrices, and synthetic bone 
substitutes, including ceramics (e. g. tricalcium phosphate, hydroxyapatite, …) and 
composite grafts. More recently, also glass- and metal-based scaffolds have been 
developed. As natural biomaterials provide only minimal structural support, synthetics 
are mainly used for the regeneration of large bone defects. (20, 21) 
The osteoinductive material used in the experimental work presented in this thesis is a 
degradable, synthetic product based on hydroxyapatite (Actifuse™ Microgranules from 
Apatech®). An additional silicate substitution changes the surface charge of the material 
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attracting more of the proteins that bind osteoblasts and therefore accelerates bone 
formation. In addition, an optimised structure with interconnected porosity encourages 
and supports rapid bone formation. 
2) Cells: including enabling methodologies for the proliferation without loss of 
progenitor cell capacities and osteogenic differentiation of cells, as well as acquiring the 
appropriate source of cells. Based on many reasons presented in chapter 1.3, 
mesenchymal stem cells (MSC) are the most widely used for the purpose of bone tissue 
engineering. 
3) Biomolecules: including growth and differentiation factors. Fibroblast growth factor-
2 (FGF-2) is effective in MSC in vitro expansion while preserving their osteogenic 
potential (22, 23), whereas a cocktail containing dexamethasone, β-glycerophosphate 
and ascorbic acid-2-phosphate is typically used to induce osteogenic differentiation of 
MSC (24). 
Figure 1.4 Tissue engineering 
approaches. Tissue engineering 
approaches are classified into three 
categories: (i) cells alone, (ii) cells with 
scaffolds, and (iii) scaffolds alone. Each 
one of these approaches can be 
enhanced by in vitro 
microenvironmental factors before 
application as a tissue substitute. 
(Source (19)) 
 
In addition to having a therapeutic application, where the tissue is either grown in a 
patient or outside the patient and transplanted, tissue engineering can have diagnostic 
applications where the tissue is made in vitro and used for testing drug metabolism and 
uptake, toxicity, and pathogenicity (25). 
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1.3 MESENCHYMAL STEM CELLS 
Cells used for bone tissue engineering need to fulfill certain requirements. Apart from 
the prerequisite of having the consistent potential to differentiate towards the 
osteogenic lineage, the ideal cells should be easily accessible by a minimally invasive 
procedure and be highly proliferative in vitro without being mutagenic in vivo. Other 
points to be avoided are immunorejection and graft-versus-host disease. These negative 
side effects, as well as contamination with diseases such as hepatitis and HIV can be 
prevented when using autologous instead of allogeneic or even xenogeneic transplants. 
Even though autologous osteoblasts are the cell source being most connatural with fully 
differentiated bone tissue, their use is constrained by their invasive and destructive 
method of isolation. Moreover, osteoblasts are not capable of extensive proliferation to 
gain sufficient cells for tissue engineering purposes. 
Pluripotent stem cells, as embryonic stem cells or induced pluripotent stem cells, on the 
other hand, are easily expandable and can commit into a large number of cell types 
including bone cells, but are prone to forming teratomas (26-29). In addition, the use of 
embryonic stem cells always carries ethical concerns. 
Therefore, most tissue engineering approaches focus on the use of autologous adult 
Mesenchymal Stem Cells (MSC). These multipotent cells are capable of in vitro 
differentiation into mesodermal cell lineages, like osteoblasts, chondrocytes and 
adipocytes. Their in vitro differentiation capacity towards other lineages, including 
cardiomyocytes, endothelial cells, pericytes, neurons and astrocytes, has also been 
proposed by several groups, but is still controversial (30-34). In vivo, expanded MSC 
demonstrated tissue engraftment and differentiation into lineages as cardiomyocytes 
(32), endothelial cells (35-37), vascular smooth muscle cells (36), pericytes (35) and 
bone (38).  
Nowadays MSC have been found to reside in many adult tissues such as liver, muscle, 
lung, spleen, aorta and thymus (30), where they represent a rare population localized in 
small niches, specialized local microenvironments that protect the stem cells from 
differentiation and apoptotic stimuli or uncontrolled proliferation (39).  
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Right after tissue harvest and cell isolation, MSC are still a minor fraction within a very 
heterogeneous cell population, which gradually becomes more homogeneous 
throughout cell expansion on tissue culture plastics in the appropriate media and 
culture conditions. MSC are thought to home to damaged tissues, where they support 
wound healing and hematopoiesis, but many of the native functions of MSC remain 
poorly understood. When engrafted at sites of tissue injury, MSC differentiate into 
connective tissue elements, support vasculogenesis and secrete cytokines and growth 
factors that facilitate healing (40). In addition, MSC have been shown to be 
hypoimmunogenic, immunosuppressive and immunoregulatory (41).  
MSC fate is influenced by a multitude of factors. Not only growth factors, but also 
biophysiological and mechanical stimuli, such as pH, temperature, oxygen and nutrient 
delivery as well as matrix elasticity or fluid shear provide lineage-specific stimulation in 
a spatially and temporally controlled manner (42). Even though MSC are expandable in 
vitro, they gradually loose their differentiation potential and finally undergo senescence 
(43, 44). More importantly, they can develop karyotype abnormalities in vitro due to 
long-term culture (45). 
As ex vivo expansion is necessary for genetic modification and to obtain a sufficient cell 
number for tissue engineering of grafts with a clinically relevant size, the culture 
duration needs to be minimized and the conditions of culture must be optimal. 
As the field of MSC research expands rapidly, investigators developed different methods 
of isolation and expansion and different approaches to characterize these cells. To 
address this issue, the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy (ISCT) has proposed minimal criteria to define 
human MSC: 1) MSC must be plastic-adherent when maintained in standard culture 
conditions; 2) MSC must express CD105, CD73 and CD90, and lack expression of CD45, 
CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules; and 3) MSC must 
be able to differentiate to osteoblasts, adipocytes and chondroblasts in vitro (46). 
The most commonly used and characterized MSC are derived from bone marrow 
(BMSC) (47) and the stroma vascular fraction of adipose tissue (ASC) (48).  
The idea that bone marrow contains osteogenic precursor cells was first demonstrated 
in the mid-20th century, when several research groups showed that bone marrow in 
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vitro or implanted in vivo gave rise to bone tissue (49-51). The similarity between the 
mesenchymal stem cell properties of ASC and BMSC, including their osteogenic potential 
in vitro, was discovered only recently (31, 52). Also the confirmation that ASC can 
differentiate into bone tissue in vivo is relatively novel, as it was first observed in the last 
few years (53, 54). 
Cells from both sources share many biological characteristics and are very promising for 
regenerative medicine approaches. Nevertheless, each of them has pros and cons in 
comparison to the other. Adipose tissue, for instance, is more easily accessible and more 
abundant than bone marrow and also contains higher numbers of colony-forming 
(clonogenic) cells, which is an advantage for clinical applications (55-57). Furthermore, 
it has been shown that the yield of clonogenic cells obtained from bone marrow, but not 
from adipose tissue, decreases with the age of the patient (58). Schmuck et al. recently 
discovered that aging even increases the abundance of ASC, although this may be due to 
an accumulation of non-replicative ASC (59). 
A study comparing the yield of adherent cells, growth kinetics, cell senescence, in vitro 
adipo-, osteo- and chondrogenic differentiation capacity and gene transduction 
efficiency of ASC and BMSC derived from the same patients by De Ugarte et al. revealed 
no significant differences between the two kinds of MSC (55). On the other hand the in 
vivo osteogenic capacity of ASC is still controversial and seems to be less reliable then 
that of BMSC. While some research groups claim no difference in in vivo osteogenic 
potential comparing ASC and BMSC (54), others were not able to reproduce those 
results (60-62). Although studies carried out in our lab indicate an in vivo osteogenic 
potential of ASC (17), BMSC appear to produce bone tissue more easily and 
reproducibly. 
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1.4 GENETIC MODIFICATION OF MSC 
As described in the previous chapter, MSC are an attractive cell source for tissue 
engineering. In many cases, however, it is challenging to achieve the desired outcome 
with MSC alone. Breitbach et al., for instance, showed the risk of bone formation after 
BMSC injection into the infarcted heart (63). Similar problems faced De Bari et al. when 
implanting in vitro pre-differentiated MSC which de- and re-differentiated from a 
chondrogenic towards a myogenic phenotype and finally were cleared (64). However, 
adding specific factors, either directly as proteins or via gene transfer, often leads to 
better results (65, 66). Wojtowicz et al. recently reported that overexpression of the 
osteogenic transcription factor Runx2 in MSCs accelerated healing of critical-sized 
defects compared to unmodified MSCs (67). Similar results were described when 
implanting MSC overexpressing BMP4. These BMP4-MSC showed a better in vivo bone 
formation capacity than control cells (68).  
Gene therapy is ‘the use of genes as medicine’ involving the transfer of a therapeutic, or 
working, copy of a gene into patient’s cells instead of using drugs or surgery. The 
advantage of gene therapy over simple addition of the protein of interest is that the 
delivered gene leads to continuous production of the therapeutic factor and thus allows 
long-term treatment (69). 
Various gene delivery strategies can be used to transfer genes of interest into damaged 
tissues. In vivo applications involve the direct injection of viral or DNA vectors either 
systemically into the host or locally into the target tissue. As the required vector 
concentration to achieve therapeutic effects needs to be very high, those methods are 
associated with possible risks of toxic effects. 
A different approach constitutes the genetic modification of progenitor cells ex vivo. 
Here, gene delivery takes place while cells are in culture. Advantages of this technique 
are that cell transduction, expansion, cell population selection, external delivery of 
growth factors and differentiation signals, as well as other chemical or physical 
alterations to the culture environment can be achieved prior to transplantation into 
patients. Afterwards, the genetically modified cells can be delivered either directly, in an 
encapsulated form, or as tissue-engineered constructs comprised of cells seeded into 
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scaffolds. With this approach the patients’ safety can be improved, as the host immune 
or inflammatory response to viral particles, or toxic effects from transfection reagents, 
are avoided (70). 
 
1.4.1 GENE THERAPY VECTORS 
In order to channel the specific nucleotide sequences inside host cells, non-viral and 
viral vectors can be used. 
Although novel non-viral systems have continued to emerge as innovative vehicles for 
controlled gene delivery, viral vectors remain the most efficient means by which 
exogenous genes can be introduced and expressed by cells. 
Viral vectors can be divided into integrating and non-integrating vectors. The latter 
comprise adeno-, adeno-associated- and herpesviral vectors, which do not replicate with 
the host genome and are rapidly lost with cell proliferation. Therefore, they lead to 
transient gene expression unless they are used to transduce post-mitotic cell types. 
Adenoviral vectors lead to transient expression in any case, since they are highly 
immunogenic and are cleared by the host immune system within 2 weeks of delivery 
(71). 
Retroviral vectors, in contrast, are the most commonly used vehicles for stable gene 
transfer into various cell types. These vectors can integrate into the host genome to 
provide long-term transgene expression in the target cells and are passed on to 
daughter cells after cell division (72). Like all other viral vectors, they are derived from 
wild-type viruses by exploiting some of their biological features , like infectivity, 
integration, strong overexpression, on the one hand and by eliminating pathogenic 
characteristics, such as replication in the infected cells, on the other hand. The 
generation of a retroviral vector from a wild-type retrovirus is described here in more 
detail as a general example. 
Wild-type retroviruses are a class of enveloped viruses that contain a single-stranded 
RNA molecule as their genome. The principle feature of this family is its replicative 
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strategy, which includes reverse transcription of the viral RNA into linear double 
stranded DNA and the subsequent integration of this dsDNA into the genome of the host 
cell. RNA polymerase II from the host cell later transcribes the viral genome into mRNA, 
based on which the corresponding proteins will be produced and new viral particles can 
be assembled. As they bud from the host cell they are finally covered by a lipid bilayer 
derived from the cell membrane of the host cell containing virus-encoded surface and 
transmembrane glycoproteins (70). 
Retroviral vectors are engineered to carry a transgene of interest into a target cell, 
without being replication-competent in order to avoid pathogenic effects. Generally, the 
retroviral vectors are composed of the therapeutic transgene and the cis-acting 
elements of the viral genome: attachment sites (att), 5’- and 3’-Long Terminal Repeats 
(LTR, made of the U3, R and U5 sequences), the polypurine track (PPT), the primer-
binding site (PBS) and the packaging signal (ψ). As demonstrated by Choulika et al., the 
elimination of any of the viral cis-acting sequences leads to a nonfunctional retroviral 
system (73). The attachment sites, for instance, allow efficient integration of the viral 
DNA into the host genome through interactions with the enzyme integrase. The 
packaging signal is necessary for the encapsulation of the retroviral genome into viral 
particles. While PBS, PPT, and the LTR R sequence are required for its reverse 
transcription and transgene expression, the LTR U3 and U5 sequences are necessary for 
the integration of the reverse-transcribed retroviral material. In addition, the 5' LTR acts 
as an RNA pol II promoter.  The trans-acting viral genes that code for the viral core 
protein (gag), for the reverse transcriptase and integrase (pol), as well as for the surface 
and transmembrane components of the viral envelope proteins (env), are removed 
(Figure 1.5). Those three genes, which are necessary for the generation of functional 
retroviral particles, are co-expressed in so-called packaging cells through independent 
helper plasmids, so that infective, but non-replicating, viral vector particles can be 
produced (70). 
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Figure 1.5 Structures of the 
genomes of MLV and an MLV-
derived viral vector. The trans-
acting viral genes “gag”, “pol” and 
“env” are replaced by the 
transgene. Therefore retroviral 
vectors are replication-
incompetent but allow high-level 
expression of therapeutic genes. 
 
There are three subfamilies of retroviruses from which retroviral vectors can be 
derived: oncogenic retroviruses, lentiviruses and spumaviruses. The latter two are so 
called complex viruses. While lentiviral vectors possess the advantages that they are 
capable of transducing non-dividing cells, spumaviral vectors are rather unconventional 
as many features in their replication cycle are different from those of onco- and 
lentiviral vectors. In addition they can be toxic to cultured cells (74). 
Oncogenic retroviruses however are classified as simple retroviruses, as their genome is 
less complex. It is limited to transduction of dividing cells, as it requires breakdown of 
the nuclear membrane before it can integrate into the host genome. Murine leukemia 
virus (MLV)-based oncogenic retroviral vectors are one of the most frequently used 
gene delivery vehicles in marking studies, as well as in clinical investigations (68, 72). 
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1.5 ANGIOGENESIS 
1.5.1 VASCULARIZATION IN BONE TISSUE ENGINEERING 
Induction of angiogenesis is a crucial aspect in the development of regenerative 
medicine approaches that require rapid vascularisation of tissue-engineered grafts.  
As any tissue that is more than about 200 microns thick needs a vascular supply in order 
to ensure cell survival and function, also tissue engineered constructs with a clinically 
relevant size have to be connected to the host vasculature. A non-vascularized graft is 
nourished by simple diffusion of oxygen and nutrients. However, the survival of tissue-
engineered constructs in vivo depends on the provision of an adequate blood supply to 
the tissue as well as the capacity of the engineered microcirculation to connect with the 
existing recipient circulation. Lack of vascularization in the centre of large cell-
containing constructs invariably leads to ischemia followed by necrosis within the first 
week after implantation (Figure 1.6) (75).  
Figure 1.6 Histological sections of 
large-size osteogenic grafts stained with 
McNeal tetrachrome 12 weeks after 
implantation. Constructs displayed 
three distinct zones according to the 
vascular supply: an outer one including 
newly formed bone tissue (red stain); a 
middle zone formed by a fibrous 
connective tissue (violet stain); and a 
central zone containing only empty 
pores. The non-degraded scaffold is stained brown. (Adapted from (76)) 
The supply of nutrients and oxygen to the cells and the clearance from waste products 
are not the only functions of blood vessels. They also allow the recruitment and 
extravasation of cells and growth factors, which may improve tissue regeneration and 
formation. In bone it has been shown that vascularization establishes the conduit for a 
series of highly specialized cells involved in the regulation of osteogenesis, such as 
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osteoblasts and osteoclasts (77). In particular, bone endothelium has been found to 
actively recruit circulating cells and to direct hematopoietic cell homing to the bone 
marrow. Moreover, consistent with their putative roles in regulating osteogenesis, 
osteoclastogenesis, and bone remodelling, endothelial cells synthesize and display or 
secrete many factors known to exert major effects in controlling the differentiation, 
metabolism, survival and function of bone cells. Conversely, bone endothelial cells are 
also capable of responding to bone modulators (78).  
In fracture repair both osteoblasts and osteoclasts express VEGF, thereby contributing 
to local angiogenesis. In addition to endothelial cells also BMSC, osteoblasts and 
osteoclasts possess VEGF receptors and are therefore influenced by this angiogenic 
factor (78-81). 
In summary, vasculature plays a major role in the generation and homeostasis of bone, 
without which bone tissue repair or rejuvenation would be impossible. In addition, 
modifications in the blood supply correlate with numerous skeletal pathologies, 
including osteoporosis or osteopetrosis, inflammatory bone loss and tumor-associated 
osteolysis (78). 
 
1.5.2 STRATEGIES TO ACCELERATE THE ESTABLISHMENT OF A VASCULAR 
NETWORK IN BONE GRAFTS 
Different strategies have been investigated to establish blood perfusion in osteogenic 
grafts. In surgical techniques, like the flap- or arterio-venous loop- fabrication, the bone 
graft is wrapped in vascularized host tissue, or an arterio-venous loop is placed in close 
proximity of the construct (e.g. placed in a groove within the scaffold) in order to favor 
vascular ingrowth. The donor site morbidity, however, is still a problem when applying 
these techniques. Moreover, flap pre-fabrication has the major clinical disadvantage of 
requiring a two-step surgery, the cost and complexity of which could limit its potential 
for future clinical applications (17, 82, 83).  
Biomaterial based methods to engineer vascularized bone tissue are diverse. One 
approach is the design of nano-/micro-fiber combined scaffolds, which provide 
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mechanical support for bone repair and angiogenesis at the same time, and scaffold 
microfabrication aiming on the inclusion of a network with a vascular geometry in a 
biocompatible polymer. Microfabrication is mainly applied to the establishment of a 
complex branching vascular tree in soft organs. A hard tissue such as bone has an 
increased level of complexity, which demands microfabrication methods to be adapted 
in order to simultaneously address design and mechanical issues (83). The loading of 
scaffolds with pro-angiogenic factors is another variant in biomaterial-based approaches 
(84). Even though angiogenesis can be enhanced using this strategy, the release of 
growth factors with optimal kinetics and the achievement of local concentrations that 
are both safe and therapeutic remain unresolved challenges. In addition, the instability 
of the factors in vivo and the required high doses of recombinant protein cause an 
escalation in therapy costs (83). These problems can be overcome using genetically 
modified cells for the delivery of angiogenic factors (see chapter 1.4). 
On the other hand, a closer approximation to the physiological in vivo situation can be 
created by the co-culture of osteogenic and vasculogenic precursor cells. Although 
normally endothelial cells and osteoblasts are mainly isolated from different sources 
(85, 86), from the clinical point of view it is more convenient to obtain the two cell 
populations from a common cell source, as has been described for adipose tissue and 
bone marrow (87, 88). 
Although many strategies are currently under investigation, the need to achieve rapid 
vascularization of large-size grafts still remains a major challenge in the field of tissue 
engineering and a bottleneck for the development of clinical applications. 
 
1.5.3 MOLECULAR REGULATION OF ANGIOGENESIS 
Blood vessels provide efficient and simultaneous transport of gases, liquids, nutrients, 
signaling molecules and circulating cells between tissues and organs and insufficient 
blood supply causes tissue ischemia, leading to necrosis. 
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In the human body oxygenated blood is pumped from the heart through arteries into 
arterioles and finally reaches an extensive network of capillaries. Because of their wall 
structure and the large surface-area-to-volume ratio, these vessels form the main site of 
exchange of nutrients between blood and tissue. Afterwards, the oxygen-depleted blood 
passes through venules and veins back to the heart (Figure 1.7). From there, blood is 
then transported to the lungs, where it is replenished with oxygen. 
 
Figure 1.7 vessel composition. Blood flows 
from the heart through arteries into 
arterioles and finally into a branched 
capillary network where an exchange 
between the blood stream and the 
surrounding tissue occurs. The blood is 
thereafter returned through venules and 
veins to the heart. All vessels consist of a 
tube of endothelial cells. In addition, 
capillaries are covered and stabilized by 
pericytes, while arterioles and venules are 
completely invested by vascular smooth 
muscle cells. The walls of arteries consist of 
vascular smooth muscle cells packed into an internal and external elastic lamina and an additional 
fibroblastic layer. (Adapted from (90))  
 
 
All these different vessel types are based on a tube of endothelial cells (EC). Dependent 
on their biological function, they are equipped with additional structures. Capillaries, for 
instance, consist of endothelial cells surrounded by a basement membrane and a sparse 
layer of pericytes embedded within the endothelial cell basement membrane, while 
arterioles and venules have an increased coverage of mural cells. Here, endothelial cells 
are overlaid with a basement membrane and an internal elastic lamina which is 
completely invested with vascular smooth muscle cells that form their own basement 
membrane and are circumferentially arranged, closely packed and tightly associated 
with the endothelium. The walls of larger vessels (arteries) consist of three specialized 
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layers: an intima composed of endothelial cells, a media of smooth muscle cells and an 
adventitia of fibroblasts, together with matrix and elastic laminae. Smooth muscle cells 
and elastic laminae contribute to the vessel tone and mediate the control of vessel 
diameter and blood flow (Figure 1.7) (89). 
New blood vessels form by different mechanisms, including de novo assembly by 
endothelial precursor cells or angioblasts (vasculogenesis), splitting of existing vessels 
(intussusception), and enlargement of the vasculature through sprouting, proliferation 
and remodeling (angiogenesis). Vasculogenesis appears to be largely confined to the 
formation of the first primitive vascular structures as well as the large axial vessels in 
the early embryo. Conversely, angiogenesis appears to be the main process for the 
formation of the vast majority of blood vessels during development, tissue repair, or 
disease processes. In response to insufficient local supply of oxygen (hypoxia), tissues 
up-regulate the expression of proangiogenic growth factors. These signals activate 
receptors in the endothelium and lead to phenotypic and functional changes in some 
ECs. As they extend long philopodia, these are called tip cells are able to sense gradients 
of growth factors, become motile, invasive, and initiate sprouting from the basal (outer) 
surface of the blood vessel tubules. Other ECs form the stalk of the growing sprout and 
stay behind to maintain tissue perfusion. Due to substantial stalk cell proliferation 
angiogenic sprouts extend, until they meet with other sprouts or capillaries, and are 
finally converted into new blood-carrying capillaries. Later steps of vascular 
morphogenesis involve the pruning and remodeling of the newly formed and initially 
dense vessel network (Figure 1.8). Finally, tip cells recruit pericytes to the new sprouts. 
The physical contact between ECs and pericytes induces a quiescent, non-sprouting 
phenotype and therefore stabilizes blood vessels and promotes a mature, non-
angiogenic state of the vasculature, independent of further angiogenic stimuli. Pericytes 
provide survival signals to endothelial cells and stabilize new vessels by regulating 
endothelial function and differentiation (91, 92). Previous results from Dor et al. and 
Ozawa et al. identified that the expression of the proangiogenic factor VEGF must be 
sustained for approximately 4 weeks in order to stabilize the newly formed vessels in 
vivo (93, 94).  
                                                                                                                                           INTRODUCTION 
31 
As mentioned, angiogenesis is stimulated by a variety of growth factors. The most potent 
and specific pro-angiogenic factor is vascular endothelial growth factor-A (VEGF-A). 
VEGF-A binds and activates the receptor tyrosine kinases VEGFR1 and VEGFR2 on the 
EC surface and is an essential positive regulator of blood vessel growth. Recently, VEGF 
has been shown to control angiogenesis not only by directly stimulating endothelial 
cells, but also through the recruitment and activation a heterogeneous mix of myeloid 
cells recruited from the circulation. These cells are trapped at the sites of angiogenesis 
and are pro-angiogenic through the actions of paracrine factors (95). 
 
Figure 1.8 Angiogenic sprouting of blood 
vessels. Pro-angiogenic factors (e.g. VEGF) 
promote a fraction of endothelial cells to 
develop into tip cells (yellow) with long 
philopodia, which lead the growing 
sprout. Other ECs form the sprout stalk by 
extensive proliferation or stay behind to 
maintain tissue perfusion (red). When tip 
cells contact other tip cells or vessels, they 
establish new connections via cell bridges 
(orange) and finally form new perfused 
vessels. New sprouting is initiated at 
other sites and additional ECs are 
generated by proliferation (purple). 
(Source (91))        
 
VEGF-A is a heparin-binding, disulfide-linked dimeric glycoprotein that exists as 
numerous splice variant isoforms. Longer isoforms, as VEGF183, VEGF189 or VEGF206, 
possess strong heparin-binding domains and are therefore strongly attached to the 
extracellular matrix of secreting cells. Short isoforms, in contrast, as VEGF121 or VEGF145 
lack these sequences and are therefore diffusible. The most biologically active VEGF-A is 
VEGF165 (VEGF164 in rodents), which binds heparin with an intermediate affinity and 
thus sticks to the extracellular matrix with a frequency of 50-70% (96, 97). 
Subsequently VEGF165/164 remains localized in the microenvironment around its 
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producing cell and does not distribute uniformly in the tissue. As a consequence, 
sustained over-expression of heterogeneous levels by different cells do not average each 
other and even rare areas of high expression, which form VEGF-hotspots, are sufficient 
to induce aberrant angiogenesis marked by the growth of hemangioma-like vascular 
tumors. As shown in figure 1.9, angiomas are aberrant bulbous vessels characterized by 
a loss of normal pericyte coverage and its substitution with smooth-muscle-like mural 
cells. They do not stabilize and remain VEGF dependent, thus growing into large, blood-
filled vascular sacs, which eventually bleed and cause the animal death (93, 98).  
 
 
 
 
Figure 1.9 Normal versus aberrant angiogenesis. Endothelial cells are stained in green, pericytes in red 
and smooth muscle cells in blue. Normal capillaries are stabilized by pericytes, while angioma-like 
structures retain only few and dysfunctional pericytes (arrowhead), but are associated with smooth 
muscle actin-positive mural cells (arrow). Normally, only arteries and veins are covered by smooth muscle 
cells. Scale bar: 50µm. (Adapted from (93)) 
 
Our group previously found that the induction of normal and stable angiogenesis or 
aberrant angioma growth depends on the amount of VEGF in the microenvironment 
around each producing cell, and not on the total dose of the factor in the tissue (93, 98). 
In fact, whenever the microenvironmental VEGF doses can be expressed homogeneously 
through the tissue, normal, stable and functional angiogenesis is induced over a wide 
range of VEGF expression levels, up to a discrete threshold, above which angioma 
growth occurs (Figure 1.10).  
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Figue 1.10 Total versus micro-
environmentally controlled VEGF 
expression level in angiogenesis. 
Manipulation of the total dose of VEGF 
gene delivery by dilution of a 
heterogeneous population of VEGF-
overexpressing cells with untreated cells 
cannot prevent the development of 
aberrant vasculature. If the 
microenvironmental distribution of 
expression level is controlled by the use 
of clonal populations, in which every cell 
expresses the same amount of VEGF, 
normal angiogenesis can be induced over a wide range of doses. However, above a dose-dependent 
threshold normal angiogenesis switches to an aberrant phenotype. (Adapted from (93)) 
 
Control over the microenvironmental distribution of VEGF doses for therapeutic 
purposes can be achieved via the genetic manipulation and selection of progenitor cells 
ex vivo before re-implantation. Implantation of clonal populations, in which every cell 
has the same number of copies and site of integrated retroviral vectors, and therefore 
expresses the same VEGF dose, provided a clear proof-of-concept of the functional and 
therapeutic implications of VEGF dose control at the total or microenvironmental level 
(93, 98). However, this approach requires excessive time, costs and cell expansion, 
making it unsuitable for a clinical application (99). Therefore, in order to translate this 
biological concept into a clinically applicable therapeutic strategy, we recently 
developed a Fluorescence-Activated Cell Sorting (FACS)-based technology to predict the 
level of VEGF expression in single cells. VEGF expression was quantitatively linked to 
that of a FACS-quantifiable syngenic cell surface marker, i.e. a truncated version of CD8a 
(Figure 1.11). In this way, high-throughput purification of cells homogeneously 
expressing specific levels from a heterogeneous progenitor population could be 
achieved rapidly, without the need to expand and screen individual clones (100). 
Rapidly purified populations induced only normal, mature and functional microvascular 
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networks, and avoided completely angioma growth, both in normal (100) and 
chronically ischemic muscle tissue (101). 
 
 
 
 
 
 
 
Figure 1.11 Viral vector genome coding for VEGF-IRES-truncated CD8a, therefore allowing VEGF-
secretion to be correlated with CD8 accumulation on the cell surface. Top: The coding sequences for 
VEGF164 and truncated CD8a (tr. CD8a) were linked through an Internal Ribosomal Entry Site (IRES) 
sequence in a bicistronic retroviral vector construct (pAMFG-rVICD8). Bottom: Schematic representation 
showing co-expression of both genes at a fixed ratio from the bicistronic mRNA, so that the amount of 
VEGF secreted (green molecules) is correlated to that of tr. CD8a retained on the cell surface (red 
molecules), which can be quantified. 
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Rapid vascularization of tissue-engineered grafts is a major bottleneck in the 
development of regenerative medicine approaches. In order to overcome this limitation, 
we aimed to develop a bone tissue engineering strategy combining cell therapy with 
pro-angiogenic gene therapy. To this end, we sought to determine the potential of 
genetically modified MSC derived from bone marrow and adipose tissue overexpressing 
VEGF. To develop a MSC-based platform for bone tissue engineering endowed with an 
increased vascularization capacity, two facts need to be considered: 
1) It is well known that MSC rapidly lose their differentiation potential after isolation 
and during in vitro expansion (43, 44). Therefore, in order to preserve their progenitor 
properties, it is crucial that genetic modification takes place both, with high efficiency, so 
as to minimize the need for cell selection, and with minimal expansion of progenitors. 
2) VEGF is the master regulator of angiogenesis. However, as described in the previous 
sections (chapter 1.5), excessive doses can cause deleterious effects and it is desirable to 
control its expression in each producing cell, since it remains localized in the 
microenvironment after secretion and different levels do not average each other in 
tissue. 
In order to overcome both of these limitations, we took advantage of a high-throughput 
technology we recently developed (100) to rapidly purify populations of genetically 
engineered myoblasts secreting a desired level of a transgene based on fluorescence-
activated cell sorting (FACS). 
As a first step (Chapter 2), we sought to develop an optimized technique to realize high-
efficiency retroviral vector transduction of both primary bone marrow and adipose 
tissue derived MSC in the initial culture stages, before the first passage. This is crucial in 
order to achieve genetic modification while avoiding a prolongation of in vitro culture. 
Furthermore, we sought to rapidly purify specific sub-populations of the transduced 
MSC expressing different VEGF levels already at the time of the first passage. 
Using these genetically modified MSC as a tool, in Chapter 3 we investigated the 
potential of VEGF-expressing human bone marrow-derived mesenchymal progenitors:  
1) to increase the vascularization of osteogenic grafts and  
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2) to efficiently generate bone tissue.  
In order to minimize variables and to rigorously determine whether transduction, FACS-
purification or VEGF-expression affected the progenitor properties of genetically 
modified MSC, non-critical size grafts were implanted ectopically in a well-established 
nude rat model. 
Finally, the thesis is summarized and discussed in Chapter 4. This chapter includes 
perspectives of ongoing projects introducing the potential of genetically modified MSC 
to control angiogenesis, both positively and negatively, in other fields of regenerative 
medicine, including heart revascularization after infarction and cartilage regeneration.  
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2.1 ABSTRACT 
Adult mesenchymal stem/stromal cells (MSC) are a valuable source of multipotent 
progenitors for tissue engineering and regenerative medicine, but may require to be 
genetically modified to widen their efficacy in therapeutic applications. For example, 
over-expression of the angiogenic factor vascular endothelial growth factor (VEGF) at 
controlled levels is an attractive strategy to overcome the crucial bottleneck of graft 
vascularization and to avoid aberrant vascular growth. Since the regenerative potential 
of MSC is rapidly lost during in vitro expansion, we sought to develop an optimized 
technique to achieve high-efficiency retroviral vector transduction of both adipose 
tissue- and bone marrow-derived MSC (ASC and BMSC) and rapidly select cells 
expressing desired levels of VEGF with minimal in vitro expansion. 
The proliferative peak of freshly isolated human ASC and BMSC was reached 4 and 6 
days after plating, respectively. By performing retroviral vector transduction at this 
time-point, >90% efficiency was routinely achieved before the first passage. MSC were 
transduced with vectors expressing VEGF quantitatively linked to a syngenic cell-surface 
marker (truncated CD8). Retroviral transduction and VEGF expression did not affect 
MSC phenotype nor impair their in vitro proliferation and differentiation potential. 
Transgene expression was also maintained during in vitro differentiation. Furthermore, 
three sub-populations of transduced BMSC homogeneously producing specific low, 
medium and high VEGF doses could be prospectively isolated by flow cytometry based 
on the intensity of their CD8 expression already at the first passage. 
In conclusion, this optimized platform allowed the generation of populations of 
genetically modified MSC, expressing specific levels of a therapeutic transgene, already 
at the first passage, thereby minimizing in vitro expansion and loss of regenerative 
potential.  
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2.2 INTRODUCTION 
Adult mesenchymal stem/stromal cells (MSC) are a population of multipotent 
progenitors, capable of generating bone, cartilage, fat and possibly other mesodermal 
tissues and represent a fundamental tool in regenerative medicine (1, 2). MSC have been 
described in many tissues as a pericyte-like population in close association with blood 
vessels (3), raising the intriguing possibility that they may reside in the vascularized 
stroma of every tissue. However, the most commonly used and characterized MSC are 
derived from bone marrow (BMSC) and adipose tissue (ASC), due to their abundance 
and ease of harvesting (4, 5). 
Despite their potential, it may be desirable to genetically modify MSC in order to 
increase their survival and/or differentiation in therapeutic applications. For example, 
spontaneous vascularization of tissue-engineered grafts in vivo is too slow to allow 
survival of progenitors in constructs larger than a few millimeters. In order to overcome 
this bottleneck in the generation of clinical-size grafts, it is necessary to increase their 
ability to rapidly attract a vascular supply from the host, e.g. by over-expressing an 
angiogenic factor from the implanted progenitors (6-8). 
Vascular endothelail growth factor (VEGF) is the master regulator of vascular growth 
both in embryonic development and adult tissues (9). When expressed at the 
appropriate dose, VEGF can start the complex cascade of events leading to the formation 
of stable and functional new blood vessels (10). However, sustained expression is 
required for about 4 weeks in order to avoid regression of newly induced unstable 
vessels (11, 12). 
Non-integrating gene therapy vectors are progressively lost during cell expansion and 
lead to short-term and variable expression. Gene expression is thus less controllable, 
making it challenging to achieve a desired therapeutic effect. Integrating vectors, such as 
retroviral vectors on the other hand, replicate with the host genome and ensure 
constant expression throughout cell expansion (13, 14). 
MSC have been shown to rapidly lose their differentiation potential during in vitro 
expansion (15, 16). Therefore it is crucial that genetic modification takes place both with 
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high efficiency, in order to minimize the need for cell selection, and with minimal in vitro 
manipulation of progenitors. 
Therefore, here we sought to develop an optimized technique to achieve rapid and high-
efficiency transduction of primary MSC from both bone marrow and adipose tissue with 
minimal in vitro expansion, together with high-throughput purification of the progenitor 
populations expressing specific transgene levels based on fluorescence-activated cell 
sorting (FACS). Greater than 90% transduction efficiency of freshly isolated BMSC and 
ASC could be routinely achieved and FACS-purification was possible already at the time 
of the first passage, while no loss of in vitro proliferation and differentiation potential 
was caused by either the genetic modification or the FACS-sorting. 
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2.3 MATERIALS AND METHODS 
MSC isolation and culture 
Human primary ASC and BMSC were isolated from liposuction and bone marrow 
aspirates, respectively. The aspirates were obtained from healthy donors as previously 
described, after informed consent by the patients and approval by the local ethical 
committee. Briefly, subcutaneous adipose tissue was digested in 0.075% type-II 
collagenase (Worthington) in PBS and plated at a density of 5.5 x 103 nucleated 
cells/cm2 (17). Bone marrow was subjected to red blood cell lysis (18) and plated at a 
density of 105 nucleated cells/cm2. Both ASC and BMSC were cultured in α-MEM 
supplemented with 10% FBS (Gibco) and 5 ng/ml FGF-2 (BD Biosciences). Cells were 
passaged when 80% confluent and replated at a density of 3 x 103 cells/cm2. 
Colony forming efficiency (CFE) assays were performed on freshly isolated cells as 
described (19). The proliferation rate was determined by counting the number of cells at 
every passage with a Neubauer chamber (Roth), determining the number of population 
doublings from the previous passage (19) and plotting the cumulative doublings against 
the time in culture. 
 
Myoblast culture 
Primary C57Bl/6 mouse myoblasts were cultured on collagen-coated dishes in 
medium consisting of 40% F10, 40% low-glucose DMEM (both Sigma), supplemented 
with 20% FBS and 2.5 ng/ml FGF-2, as previously described (20). 
 
Cell cycle analysis 
The proportion of actively cycling cells was determined by measuring their nuclear 
DNA content by flow cytometry after staining with propidium iodide as described (21). 
The data were analyzed using the cell cycle analysis tool from FlowJo Software (Tree 
Star) using the Watson model (22). ASC (n=4 donors) and BMSC (n=3 donors) from 
duplicate dishes were analyzed at each time-point. 
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Retroviral transduction 
The optimization experiments were performed with frozen aliquots of a pooled stock 
of retroviral vector supernatant, to ensure the same titer in all conditions. Subsequent 
experiments were performed with fresh viral vector supernatants. Primary MSC were 
transduced with previously described retroviral vectors (23) according to a high-
efficiency protocol (24). Briefly, MSC were cultured in 60-mm dishes and were 
incubated with retroviral vector supernatants supplemented with 8µg/ml polybrene 
(Sigma-Aldrich) for 5 minutes at 37°C and centrifuged at 1100g for 30 minutes at room 
temperature in the dishes, followed by fresh medium replacement. 
 
Flow cytometry 
CD8a expression was assessed by staining with a FITC-conjugated anti-rat CD8a 
antibody (clone OX-8; BD Pharmingen), using previously optimized staining conditions 
(23), i.e. 2µg of antibody/106 cells in 200µl of PBS with 5% BSA. 
Expression of MSC surface markers was assessed by staining with specific antibodies 
against: CD31 (clone WM59, BD Pharmingen), CD34 (clone 581, BD Pharmingen), 
KDR/VEGFR2 (clone 89106, R&D Systems), CD73 (clone AD2, BD Pharmingen), CD90 
(clone 5E10, BD Pharmingen), CD105 (clone SN6, AbD Serotec). All antibodies were 
used at a 1:20 dilution except for CD90 (1:100). Aspecific binding was measured by 
staining with appropriate isotype control antibodies. Data were acquired with a 
FACSCalibur flow cytometer (Becton Dickinson) and analyzed using FlowJo software 
(Tree Star). Cell sorting was performed with the Influx cell sorter (Becton Dickinson). 
 
MSC immunostaining 
50%-confluent MSC cultures were fixed with 4% formalin, blocked for 1 hour with 
10% calf serum in PBS and incubated with an antibody against rat CD8a (clone OX-8, BD 
Pharmingen; 1:200), followed by an Alexa 488-conjugated chicken anti-mouse IgG 
(Invitrogen; 1:500). Nuclei were stained with DAPI (Invitrogen). 
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In vitro differentiation  
Adipogenic differentiation was induced as previously described (17). Briefly, 
subconfluent cell layers were treated with 10µg/ml insulin, 10-5M dexamethasone, 
100µM indomethacin and 500µM 3-isobutyl-1-methyl xanthine for 72 hours and 
subsequently with 10µg/ml insulin for 24 hours, repeating this 96-hour treatment cycle 
four times. Lipid droplets were detected with Oil Red-O staining. 
Osteogenic differentiation was induced by culturing MSC with α-MEM medium 
supplemented with 10% fetal bovine serum, 100nM dexamethasone, 10mM β-
glycerophosphate and 0.05mM ascorbic acid-2-phosphate for 3 weeks, as previously 
described (17). Calcium deposits were detected with Alizarin Red staining. 
Quantitative real time RT-PCR  
Total mRNA was isolated using the RNeasy Mini Kit (Qiagen) and cDNA was 
synthesized with the Superscript III Reverse Transcriptase (Invitrogen). 
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) was 
performed on a 7300 AB thermocycler (Applied Biosystem) to quantify the expression 
of the following genes: human cbfa-1/Runx2 (Forward: CGTTACCCGCCATGACAGTA; 
Reverse: GCCTTCAAGGTGGTAGCCC; Probe: CCACAGTCCCATCTGGTACCTCTCCG; 
primers=300 nM and probe=100 nM) (25); PPARγ (Applied Biosystems assay 
Hs00234592_m1; primers=900 nM and probe=250 nM). To quantify expression of the 
retroviral cassette, a specific primers-and-probe set was designed with the Primer 
Express 3 software (Applied Biosystems) to recognize the Internal Ribosomal Entry 
Sequence (IRES) (Forward: GCTCTCCTCAAGCGTATTCAACA; Reverse: 
CCCCAGATCAGATCCCATACA; Probe: CTGAAGGATGCCCAGAAGGTACCCCA; primers=400 
nM and probe=400 nM). GAPDH was used as a housekeeping gene (Forward: 
TAAAAGCAGCCCTGGTGACC; Reverse: ATGGGGAAGGTGAAGGTCG; Probe: 
CGCCCAATACGACCAAATCCGTTGAC; primers=300 nM and probe=150 nM) (26). Two 
independent cDNA samples/condition/donor were analyzed in triplicate with the 
following cycling parameters: 50°C for 2 minutes, followed by 95°C for 10 min and 45 
cycles of denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 
minute. 
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ELISA 
VEGF production was quantified in cell culture supernatants using a Quantikine rat 
VEGF immunoassay ELISA kit (R&D Systems). One ml of fresh medium was incubated on 
MSC cultured in 60-mm dishes in duplicate for 4 hours, filtered and frozen. Results were 
normalized by the number of cells in each dish and the time of incubation. 
 
Statistics 
Data are presented as means ± standard error. The significance of differences in 
multiple comparisons was evaluated using one-way analysis of variance (ANOVA) 
followed by the Bonferroni test. P<0.05 was considered statistically significant.  
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2.4 RESULTS 
Optimization of MSC transduction 
Since retroviral vectors efficiently transduce only dividing cells, we first sought to 
determine the earliest time after isolation and plating when ASC and BMSC enter the cell 
cycle and proliferation is at its peak. Cell cycle analysis was performed on samples from 
3 independent donors every day from the initial plating to the time of first confluence, 
which was reached consistently by day 12 and 14 for ASC and BMSC, respectively. ASC 
reproducibly reached a proliferation peak 4 days after isolation (52.2 ± 5.0% of cycling 
cells) that was maintained until day 7, after which replication declined with increasing 
confluence (Figure 2.1A). BMSC displayed a higher variability in the first days, but their 
growth trend was similar, proliferation reached its maximum on day 6 (54.7 ± 5.5%) 
and declined after day 10 (Figure 2.1B). 
Based on these results, we determined the optimal time to start transduction to be on 
day 4 after isolation for ASC and day 6 for BMSC. Cells were transduced twice per day up 
to 6 times with a retroviral vector expressing the cell surface marker CD8 and the 
transduction efficiency was evaluated after each round by FACS quantification of the 
CD8-positive cells. The majority of the increase in the number of transduced cells took 
place during the first 4 rounds for both ASC and BMSC (Figure 2.1C-D), while the last 2 
rounds only contributed marginal improvement. Therefore, it was determined that 4 
rounds of transduction would provide a suitable balance between efficacy and cell 
manipulation and this protocol was used to generate all cell populations for further 
analysis. 
 
 
 
 
 
 
 
 
                   NOVEL METHOD FOR GENERATING MSC EXPRESSING DEFINED VEGF LEVELS 
49 
Figure 2.1 
Optimization of MSC 
retroviral vector 
transduction. The 
proportion of ASC (A) 
and BMSC (B) in active 
proliferation (S/G2/M 
phases) was assessed 
by flow-cytometry 
analysis of nuclear 
DNA content after 
staining with 
Propidium Iodide 
during the first 12 to 
14 days after initial 
plating (n=3 each). The 
transduction efficiency of ASC (C) and BMSC (D) was assessed as a function of infection rounds (n=3 each). 
The amount of CD8-positive cells was determined by FACS after up to 6 rounds of transduction with a 
CD8-expressing retroviral vector. Naïve MSC were used as negative control (0 rounds). 
 
Generation of FACS-sortable MSC 
Freshly isolated ASC and BMSC were transduced according to the optimized protocol 
with a bicistronic retroviral vector co-expressing rat VEGF164 (VEGF) and a truncated 
version of rat CD8a (CD8) as a FACS-quantifiable cell-surface marker, joined through an 
internal ribosomal entry sequence (IRES) that allows the translation of two proteins 
from the same mRNA at a fixed ratio (27) (Figure 2.2). A retroviral vector expressing 
only CD8 was used to generate control cells. These genetically modified populations 
were used for further analysis (Figure 2.2). 
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Figure 2.2 Study design. ASC and BMSC were isolated and transduced with a bicistronic retroviral vector 
co-expressing rat VEGF164 (rVEGF164) and a truncated version of rat CD8a (tr. rCD8a). LTR = retroviral 
Long Terminal Repeats; ψ = packaging signal; IRES = Internal Ribosomal Entry Sequence. CD8-positive 
MSC were FACS-sorted to generate pure populations of transduced cells and were analyzed to determine 
the effects of retroviral transduction and transgene expression on their phenotype, as well as their in vitro 
proliferation and differentiation potential. 
Using freshly produced viral vector supernatants with the optimized protocol described 
above, a transduction efficiency >90% was routinely achieved (Figure 2.3A-B). Upon 
reaching the first confluence, MSC were FACS-purified in order to remove non-
transduced cells and to yield pure CD8-positive populations (Figure 2.3A-B), which were 
replated for all subsequent experiments. Neither sorting nor transduction affected the 
morphology of ASC and BMSC, which exhibited a spindle-shaped phenotype similar to 
that of the corresponding naïve cells (Figure 2.3C-D, brightfield). Detection of membrane 
CD8 by immunofluorescent staining confirmed the high efficiency of transduction 
(Figure 2.3C-D, Unsorted) and the lack of non-transduced cells after sorting (Figure 
2.3C-D, Sorted). 
We further investigated whether transduction or VEGF expression could change the 
phenotype of MSC populations or cause the expansion of endothelial sub-populations. 
For this purpose the expression of surface markers specific for mesenchymal (CD105, 
CD90 and CD73) and endothelial (CD31, CD34 and VEGFR2) cells was analysed by flow 
cytometry. Naïve ASC and BMSC were compared with mock-transduced cells 
(centrifuged only) and with CD8- or VEGF-expressing transduced and sorted cells. As 
shown in Table 1, first-passage naïve ASC and BMSC were almost uniformly positive for 
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all the analyzed mesenchymal markers and contained less than 0.5% of endothelial cells. 
No significant changes in the mesenchymal phenotype of manipulated MSC were caused 
by transduction and sorting or by VEGF expression, nor was the ratio of endothelial cells 
increased in any condition. 
 
 
 
 
 
 
 
 
 
 
Values are expressed as the mean ± standard error of the mean (n = 3); p = n.s. for each marker expression 
between all groups. 
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Figure 2.3 FACS-purification of transduced MSC. Representative FACS plots show that both ASC (A) and 
BMSC (B) were transduced with >90% efficiency (black plots) and that pure CD8-positive populations 
were obtained after sorting (tinted blue plots). Control naïve cells = red plots. Microscopic images of naïve 
or VEGF-expressing ASC (C) and BMSC (D), either before (Unsorted) or after (Sorted) FACS-purification. 
BF = brightfield images; CD8 = cells immunostained with an anti-ratCD8 antibody (green) and DAPI 
(nuclei, in blue). White arrows indicate the nuclei of CD8-negative cells in the unsorted populations (n=3 
each). Size bar = 100µm. 
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In vitro proliferation and differentiation of genetically modified MSC 
The effects of transduction and FACS-purification on MSC proliferative potential were 
assessed by measuring the cumulative population doublings of CD8- and VEGF-
expressing ASC and BMSC for 8 and 9 passages after sorting, respectively. These were 
compared to naïve cells and mock-transduced cells that were subjected to the physical 
manipulation involved in the transduction protocol, i.e. centrifugation for 30’ in the dish, 
but in the absence of viral vector particles. Both transduced ASC and BMSC populations 
proliferated more slowly than the naïve and centrifuged MSC during the first 2 passages 
after sorting (Figure 2.4). However, this effect was temporary and growth of transduced 
MSC resumed at the same rate as control cells approximately 10 days after the sorting 
(Figure 2.4). Therefore, transduction and sorting did not affect the intrinsic proliferative 
potential of MSC. 
 
 
 
 
 
 
Figure 2.4 In vitro proliferation of transduced MSC. The in vitro proliferative potential of CD8- and VEGF-
expressing ASC (A) and BMSC (B) was not impaired compared to that of naïve and mock-transduced cells 
over 9 passages after FACS sorting (n=3 each). 
 
The differentiation potential of the same ASC and BMSC populations towards the 
adipogenic and osteogenic lineages was determined in vitro after the first passage and 
FACS-purification. Mock-transduced, CD8- and VEGF-expressing ASC (Figure 2.5A) and 
BMSC (Figure 2.5C) were able to differentiate into both lineages similarly to the naïve 
MSC. Interestingly, in ASC from one donor with poor intrinsic osteogenic differentiation 
potential (Figure 2.5B), VEGF expression actually increased osteogenic differentiation 
compared to naïve, mock-transduced and CD8-expressing cells (Figure 2.5B). 
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Differentiation was confirmed by quantifying the expression of transcription factors that 
are responsible for initiating adipogenesis (PPAR-γ, Figure 2.5D-E) and osteogenesis 
(Runx2, Figure 2.5F-G) by qRT-PCR. The results confirmed that ASC and BMSC 
differentiation along both lineages was not impaired by retroviral transduction, FACS-
purification or VEGF expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 In vitro differentiation of transduced MSC. Naïve, mock-transduced, CD8- and VEGF-expressing 
were differentiated in vitro towards the adipogenic and osteogenic lineages. (A-C) Oil Red-O staining 
(adipogenic) and Alizarin Red staining (osteogenic) of control (C-) or differentiated (Diff.) ASC (A-B, from 
two different donors) and BMSC (C) (n=4 each). Differentiation was confirmed by quantifying the 
expression of PPAR-γ (adipogenesis, D-E) and Runx2 (osteogenesis, F-G) in expansion and differentiation 
conditions by quantitative real-time PCR (n=3 each). The graphs show relative expression compared to 
that of the housekeeping gene GAPDH. 
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Transgene expression after cell differentiation 
Retroviral vectors integrate in the host genome and their level of expression can be 
affected by remodeling of the surrounding chromatin that accompanies gene activation 
and repression during differentiation (28). Therefore, we assessed the stability of 
transgene expression by transduced MSC during differentiation. 
Transgene mRNA levels were quantified by qRT-PCR of the IRES sequence, which is 
common to the expression cassettes in both retroviral vectors used (CD8 and VEGF), so 
that the use of a single pair of primers allowed comparisons between all cell populations 
(Figure 2.6A-B). VEGF protein was measured by ELISA (Figure 2.6C-D). Both assays 
indicated that transgene expression did not decline during in vitro adipogenic or 
osteogenic differentiation compared to cells in expansion medium, and that in some 
instances it actually increased. 
 
Figure 2.6 Transgene 
expression after in vitro 
differentiation. Transgene 
expression was quantified in 
expansion culture (E) or after 
adipogenic (A) and osteogenic 
(O) in vitro differentiation of 
CD8- and VEGF-expressing ASC 
(A, C) and BMSC (B, D). 
Expression of the transgene 
mRNA levels were quantified by 
qRT-PCR (A-B). VEGF protein in 
the supernatants was measured 
by ELISA (C-D). ** p ≤ 0.01 and 
*** p ≤ 0.001 vs. cells cultured in expansion medium (n=3 each). 
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FACS-purification of MSC expressing specific VEGF levels 
In order to rapidly purify homogeneous populations expressing desired levels of 
VEGF, we employed a technology we recently developed with transduced skeletal 
myoblasts (23, 29). Previously established clonal populations of skeletal myoblasts 
transduced with the same ratVEGF-IRES-ratCD8 retrovirus and homogeneously 
expressing specific VEGF levels (23) were used as reference populations to FACS-sort 
transduced MSC expressing similar CD8 levels on the cell surface (Figure 2.7A). After 
FACS-purification, low-, medium- and high-level sorted populations produced about 12, 
79 and 154 ng/106 cells/day, respectively. As shown in Figure 2.7B, these VEGF amounts 
were remarkably similar to those produced by the corresponding reference clonal 
populations (13, 53 and 155 ng/106 cells/day, respectively). VEGF secretion by the 
FACS-purified populations was stable also 5 and 18 days after sorting (data not shown). 
Figure 2.7 FACS-purification of transduced BMSC expressing specific VEGF levels. Clonal populations of 
mouse skeletal myoblasts transduced with the same retroviral vector expressing rat VEGF and rat CD8, 
that produced specific low, medium and high VEGF levels, were used as reference populations to FACS-
purify VEGF-producing BMSC that expressed similar levels of CD8 on the cell surface (A). Quantification of 
rat VEGF164 by ELISA (B) shows that FACS sorting was successful in rapidly purifying BMSC populations 
homogeneously producing the same VEGF amounts as the corresponding reference populations. * p ≤ 0.05 
and *** p ≤ 0.001. 
                   NOVEL METHOD FOR GENERATING MSC EXPRESSING DEFINED VEGF LEVELS 
57 
2.5 DISCUSSION 
In this study we developed a tool to genetically modify primary human MSC derived 
from bone marrow and adipose tissue with high efficiency and rapidly select cells 
expressing desired levels of VEGF with minimal in vitro manipulation, so as to preserve 
their progenitor properties. This was achieved by combining an optimized transduction 
protocol with a high-throughput FACS-based purification technology we recently 
developed (29). Neither retroviral vector transduction, nor FACS-purification, nor 
expression of VEGF and the CD8 marker impaired MSC proliferation and differentiation 
potential in vitro. Transgene expression was sustained during in vitro differentiation. 
Genetic modification with integrating vectors, such as retroviruses, ensures consistent 
long-term expression of factors despite cell expansion (14). However, current methods 
for MSC transduction require that standardized proliferating cultures are established by 
replating MSC at specific densities after the first confluence is reached (30-32), so that 
until now a primary genetically modified population could not be generated before the 
second passage. In addition, high transduction efficiency is desirable, so as to minimize 
the need for selection of the expressing cells and for further expansion to reach the 
required quantity. Therefore, by rigorously determining the exact time at which freshly 
isolated MSC reach the highest proliferative activity after first plating, we were able to 
target retroviral vector transduction at the most efficient window and achieve a 
transduction efficiency of up to 95% before first confluence was reached. It should be 
noted that initial experiments to determine the optimal conditions led to efficiencies of 
only approximately 70% because they were performed with frozen aliquots of pooled 
viral vector supernatants in order to ensure standardized conditions. However, fresh 
supernatants, which have higher titers, allowed the routine achievement of >90% 
efficiency with the same protocol. 
A crucial aspect of the technique we developed is the possibility to rapidly and 
prospectively purify sub-populations of transduced cells expressing specific desired 
levels of the transgene. Currently used selection methods are designed to simply 
eliminate non-transduced cells and cannot distinguish cells expressing different levels of  
e.g. antibiotic resistance (33), or can do so only after retrospective analysis of each 
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isolated population by e.g. GFP co-expression (34). In fact, although FACS is intrinsically 
quantitative, the measured fluorescence intensity values cannot be directly translated 
into absolute amounts of transgene production. Here we overcame this limitation by 
taking advantage of a technique we recently developed to predict the absolute amount 
of expression by individual transduced skeletal myoblasts in a population by FACS, 
based on the combined use of a syngenic non-functional cell-surface marker (truncated 
CD8a) with that of immortal clonal populations as a reference (29). 
The possibility to control the expressed dose of a transgene has important therapeutic 
implications. In fact, in a heterogeneous population, high levels can be toxic and low 
levels inefficient, leading to a waste of therapeutic potential (10). For example, VEGF 
over-expression is an attractive strategy to induce therapeutic angiogenesis in ischemic 
conditions (35), as well as to increase and accelerate vascularization of clinical-size 
tissue-engineered grafts (36). However, VEGF can induce either normal and therapeutic 
angiogenesis, or aberrant angioma-like vascular growth depending on its concentration 
in the microenvironment around each producing cell in vivo, and not on its total dose 
(11, 37) as it remains bound to the extracellular matrix after secretion. Here we showed 
that MSC sub-populations homogeneously producing specific desired VEGF doses can be 
rapidly and prospectively purified from the initial transduced population already at the 
first passage, with no loss of their proliferation and differentiation potential, by 
combining the optimized transduction protocol and high-throughput FACS-based 
purification technology we developed. 
The platform described here is expected to increase the feasibility of therapeutic 
approaches based on genetically modified MSC, by ensuring both high efficiency and 
minimal in vitro manipulation. Furthermore, it should prove useful also to study the 
dose-dependent effects of genes of therapeutic interest on early-passage, primary MSC. 
In fact, the results obtained studying heterogeneous transduced populations usually 
reflect the effects of the highest levels of expression, which may obscure those of the 
lower and more physiological levels. Uniform expression of different transgene levels 
could so far only be studied in clonal populations, which are disadvantageous, as their 
generation requires extensive in vitro culture, which is known to rapdidly change the 
biological properties of mesenchymal progenitors. 
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3.1 INTRODUCTION 
Tissue engineering is a promising strategy for the replacement of large bone defects. In 
recent years, bone marrow-derived mesenchymal stromal/stem cells (BMSC) have been 
extensively used for this purpose, as they are rich in osteoprogenitors (42). However, 
one of the current limitations of bone tissue engineering is the inability to provide 
sufficient blood supply. The lack of vascularization in the centre of large cell-containing 
constructs invariably leads to ischemia followed by necrosis (75, 76). 
Apart from the supply of nutrients and oxygen to the cells and the clearance from waste 
products, which are necessary for the survival, growth and differentiation of engrafted 
cells, blood vessels also allow the recruitment and extravasation of highly specialised 
cells, as mesenchymal stem cells, hematopoietic stem cells, pre-osteoblasts and pre-
osteoclasts, which may improve tissue regeneration and formation (77, 78).  
Many different approaches to rapidly increase angiogenesis in bone tissue engineering 
are under investigation, such as surgical techniques, like the flap- or arteriovenous loop-
fabrication (17, 82, 83), biomaterial-based methods (83, 84) or the co-culture of 
osteogenic and vasculogenic precursor cells (85, 86, 102). Another strategy is the 
supplementation with pro-angiogenic factors (84). Among these, Vascular Endothelial 
Growth Factor (VEGF) is the master regulator of vascular growth both in normal and 
pathological angiogenesis and therefore is the most attractive and well-characterized 
factor for inducing the therapeutic growth of new blood vessels (96, 97). On one hand 
VEGF has a very short half-life in vivo, but on the other its expression needs to be 
sustained for approximately 4 weeks in order to allow the stabilization and persistence 
of newly formed vessels (93, 94). Therefore, the use of recombinant protein is not an 
effective therapeutic strategy, whereas the continuous secretion of the factor would be 
required. Stable long-term production in the tissue is best achieved by gene therapy, i.e. 
the delivery of the genetic sequence to allow continuous secretion of the factor by the 
target cells (103). 
In this study, we sought to use a cell-based gene therapy approach to generate bone 
grafts with an increased vascularization potential in vivo, by genetically modifying 
human BMSC to achieve sustained VEGF expression. In vivo bone formation and 
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vascularization potential by genetically modified BMSC were investigated in a well-
established nude rat model of osteogenic graft ectopic implantation. We found that VEGF 
over-expression by hBMSC caused significantly increased angiogenesis in the osteogenic 
constructs. However, this was accompanied by increased osteoclast recruitment and 
decreased bone formation specifically in the VEGF–expressing grafts. 
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3.2 MATERIALS AND METHODS 
BMSC isolation and culture 
Human primary BMSC were isolated from bone marrow aspirates. The aspirates were 
obtained from the iliac crest of healthy donors during routine orthopaedic surgical 
procedures according to established protocols, after informed consent by the patients 
and following protocol approval by the local ethical committee (EKBB, Ref. 78/07). Cells 
were isolated and cultured as described (104). Briefly, after centrifugation, the pellet 
was washed in PBS (GIBCO), resuspended in α-MEM medium (GIBCO) containing 10% 
bovine serum and 5 ng/ml FGF-2 (BD Biosciences) and plated at a density of 105 
nucleated cells/cm2. hBMSC were cultured in 5% CO2 at 37°C. When 80 - 90% 
confluency was reached, cells were replated at a density of 3000 cells/cm2. 
 
MSC genetic modification 
Primary hBMSC were transduced according to the high-efficiency protocol described 
in Chapter 2 (Helmrich et al., manuscript submitted). Briefly, starting on day 6 after 
plating, cells were transduced twice a day for a total of 4 rounds with retroviral vectors 
carrying the gene for rat VEGF164 (rVEGF) linked through an internal ribosomal entry 
site (IRES) to a truncated version of the FACS-quantifiable cell-surface marker rat CD8a 
(101). 
 
Flow cytometry and cell-sorting 
CD8a expression was assessed by staining with a FITC-conjugated anti-rat CD8a 
antibody (clone OX-8; BD Pharmingen), using previously optimized staining conditions 
(101), i.e. 2 μg of antibody/106 cells in 200μl of PBS with 5% BSA. Staining was 
performed for 20 minutes on ice. Data were acquired with a FACSCalibur flow cytometer 
(Becton Dickinson and Company) and analyzed using FlowJo software (Tree Star). Cell 
sorting was performed with an Influx cell sorter (Becton Dickinson and Company) after 
staining for CD8a according to the same protocol. 
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Osteogenic graft implantation in vivo 
Osteogenic grafts were generated as previously described (105). Briefly, 60 mm3 of 1-
2 mm silicated apatite granules (Actifuse®, Apatech) where mixed with at least 5x105 
cells embedded in a fibrin gel, with a final concentration of 20 mg Fibrinogen/ml and 6 
IU of Thrombin/ml. The resulting pellets were implanted subcutaneously in nude rats 
(RNu/Nu Charles-River, Germany) as previously described (87). After 8 weeks, the 
animals were sacrificed by inhalation of CO2. Animals were treated in agreement with 
Swiss legislation and according to a protocol approved by the veterinary office of Canton 
Basel- Stadt (permission #2167). 
 
Sample processing 
Explanted constructs were washed with PBS and fixed for 4 hours with freshly 
prepared 1% paraformaldehyde (Sigma) in PBS. Subsequently, the samples were 
decalcified according to an established protocol (Kusser and Randall, 2003). Briefly, 
granules were transferred into a PBS-based solution containing 7% w/v EDTA (Fluka) 
and 10% w/v sucrose (Sigma-Aldrich) and incubated at 37°C on an orbital shaker. The 
solution was renewed daily for 5-21 days, until the samples were fully decalcified, as 
estimated by the degree of sample stiffness. Finally the samples were embedded in OCT 
compound (Sakura Finetek), snap-frozen and 10 µm-thick sections were obtained with a 
cryotome. 
 
Analysis of angiogenesis and bone formation 
To visualize blood vessels, immunofluorescence staining was performed with the 
following primary antibodies and dilutions: mouse-anti-rat CD31 (Clone TLD-3A12; AbD 
Serotec, 1:100), rabbit-anti-mouse NG2 (Millipore, 1:200) and mouse anti-Smooth 
Muscle Actin (Clone 1A4; MPBiomedicals, 1:400). Since these antibodies cross-react 
with the corresponding human proteins, the contribution of human (donor) or rat (host) 
cells to blood vessel formation could not be distinguished. Fluorescently labeled 
secondary antibodies (Invitrogen) were used at a concentration of 1:200. 
The amount of blood vessels was quantified on images taken from CD31-stained 
sections. Three representative fluorescent images per sample (2 replicates for each of 3 
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donors) were acquired with an Olympus BX61 microscope (Münster, Germany). Vessel 
length density (VLD) was measured with Cell^P software (Olympus) by tracing the total 
length of vessels in the fields and by normalizing it to the area of the fields. 
Bone tissue was detected by staining sections with hematoxylin and eosin (H&E) and 
microscopic observation both under transmitted and fluorescent light as previously 
described (106, 107). 
 
Assessment of cell engraftment 
Human Alu repeat sequences were detected by in situ hybridization, according to a 
protocol adapted from a previously described procedure (108). A digoxigenin-labeled 
probe for human-specific Alu repetitive sequence was prepared by PCR containing 1x 
PCR buffer (Promega), 1.5mM MgCl2, 0.1mM dATP, 0.1mM dCTP, 0.1mM dGTP, 
0.065mM dTTP, 0.035mM digoxigenin-11-dUTP (Roche), 0.2µM of Alu-specific primers, 
3.75 U Platinum Taq DNA Polymerase (Invitrogen) and 50 ng of human genomic DNA. 
The following primers were used: forward 5’-cgaggcgggtggatcatgaggt-3’, reverse 5’- 
ttttttgagacggagtctcgc-3’ (108). PCR was performed with the GeneAmp® PCR System 
9600 (Perkin Elmer). After an initial denaturation step at 94°C for 5 minutes, the 
reaction was carried out with 40 cycles consisting of a denaturation step at 95°C for 15s, 
an annealing step at 65°C for 30s and an elongation step at 72°C for 30s. The PCR 
product was purified using the QIAquick PCR Purification Kit (Quiagen) according to the 
manufacturer’s protocol. 
Sections were first treated with 0.5 mg/ml Pepsin in 0.01N HCl for 10 min at 37°C and 
incubated in 0.1M TEAC (SIGMA) for 10 min at room temperature. Subsequently they 
were pre-hybridized for 30 min at 42°C in pre-hybridization buffer containing 4x SSC, 
50% deionized formamide, 1x Denhardt’s solution, 5% dextrane sulphate and 0.2µM 
bovine DNA. Afterwards the pre-hybridization buffer was replaced by fresh buffer 
containing 0.2 ng/µl digoxigenin-labeled probe. Following a denaturation step at 95°C 
for 3min and immediate cooling at 4°C for 3min, hybridization was carried out for 16 h 
at 42°C in a wet chamber. Slides were washed twice for 5 min in 2x SSC at room 
temperature and twice for 10 min at 42°C in 0.1x SSC. Finally, signals were detected by 
immunohistochemistry using anti-digoxigenin alkaline phosphatase-conjugated Fab 
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fragments (Roche) and NBT/BCIP (Roche) as substrate. The sections were 
counterstained with nuclear fast red (Sigma). 
 
TRAP-assay 
Sections were stained for tartrate-resistant acid phosphatase (TRAP) activity using 
the leukocyte acid phosphatase kit (Sigma-Aldrich). Briefly, after rinsing with water, the 
slides were stained with 0.3 mg/ml Fast Red Violet LB dissolved in TRAP buffer (0.1 M 
sodium acetate, 0.1 M acetic acid, 1 mg/ml naphthol AS-MX phosphate, pH 5.0) for 1 
hour at 37°C. After TRAP staining, nuclear staining was performed with haematoxylin 
for 1 min at room temperature. 
 
Statistics 
Data were analyzed with the software Prism 4.0a (GraphPad) and are presented as 
means ± standard error. The significance of differences was evaluated by analysis of 
variance (ANOVA) followed by a Bonferroni test. P < 0.05 was considered statistically 
significant. 
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3.3 RESULTS 
Generation of VEGF-expressing BMSC 
Primary human BMSC were transduced to express rat VEGF linked to the FACS-
detectable cell-surface marker truncated CD8a (VEGF-BMSC). Naïve BMSC and BMSC 
transduced with a retroviral vector expressing only the truncated CD8a marker (CD8-
BMSC) were used as controls. Transduction efficiencies of >90% were routinely 
achieved by the first confluence. At the first passage, the genetically modified BMSC 
were FACS-purified to eliminate non-transduced cells and to yield a pure CD8-positive 
population. 
 
VEGF-expressing BMSC improve graft vascularization despite extensive expansion 
For many clinical applications, BMSC need to be significantly expanded in vitro after 
isolation in order to generate critical-size osteogenic grafts. Therefore, we first asked 
whether genetic modification endowed transduced BMSC with a stable potential to 
effectively improve graft vascularization despite extensive expansion. BMSC derived 
from 2 independent donors were cultured until p7 after transduction and FACS-
purification, reaching a total of about 30-35 population doublings. The cells were then 
seeded onto hydroxyapatite granules and implanted subcutaneously in nude rats for 8 
weeks. Analysis of vascularization in the explanted tissues by immunofluorescence 
staining showed that the pellets loaded with both naïve or CD8-expressing BMSC 
contained mostly large-caliber regular vessels, covered with α-SMA-positive smooth 
muscle cells and only a few NG2-positive pericytes, similar to arterioles (Figure 3.1A-B). 
On the other hand, VEGF over-expression caused the appearance of large numbers of 
small-diameter vessels, which were associated with NG2-positive pericytes and 
displayed the morphology of normal and stable capillaries (Figure 3.1C). Among these, a 
few smooth muscle-covered arterioles of larger diameter were also visible (Figure 3.1C), 
showing the formation of a hierarchically structured vascular bed, with both 
conductance vessels for efficient flow and microvascular networks for metabolic 
exchange. As shown in Figure 3.1D, vessel quantification showed that VEGF-expressing 
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BMSC caused a 2- to 3-fold increase in vessel length density, compared to both naïve and 
CD8-BMSC (13.25 ± 0.8 vs. 4.5 ± 0.3 and 6.6 ± 0.8 mm/mm2, respectively, p<0.0001). 
 
 
 
 
 
 
 
 
 
Figure 3.1 In vivo angiogenesis after long-term expansion. (A-C) Immunofluorescence staining for 
endothelium (CD31, green), pericytes (NG2, red) and smooth muscle cells (SMA, cyan) in sections of 
silicated apatite granules seeded with naïve BMSC (A), control CD8-BMSC (B) or VEGF-BMSC (C) 8 weeks 
after subcutaneous implantation in nude rats (Scale bar = 50 µm). (D) The amount of angiogenesis was 
quantified by measuring vessel length density, expressed as millimeters of vessel length per square 
millimeter of tissue area [mm/mm2]. Data represent mean values ± SEM (n = 2 independent donors); ***p 
< 0.0001 compared to naïve cells. 
 
On the other hand, H&E staining and analysis under fluorescent light showed that only 
fibrous tissue, but no bone, was detectable in all constructs implanted with either 
control or VEGF-expressing BMSC (Figure 3.2), as expected with osteoprogenitors that 
had been expanded in vitro for more than 30 population doublings. 
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Figure 3.2 In vivo bone formation after long-term expansion. Composite images of entire sections 8 weeks 
after subcutaneous implantation of silicated apatite granule pellets seeded with naïve BMSC (A-B), CD8-
BMSC (C-D) or VEGF-BMSC (E-F) in nude rats. After staining with hematoxylin and eosin, sections were 
viewed under transmitted (A, C, E), as well as fluorescent light (B, D, E). Scale bar = 1 mm; n = 2 
independent donors. 
 
VEGF-BMSC improve graft vascularization, but reduce bone formation after minimal 
expansion 
In order to determine the effects of VEGF over-expression on bone formation by 
transduced osteoprogenitors, BMSC were minimally expanded, so that their intrinsic 
osteogenic capacity was not impaired by extensive in vitro culture. As shown in Figure 
3.3, two conditions were investigated: 1) populations implanted at the earliest possible 
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time, i.e. upon reaching the first confluence, which contained <10% non-transduced cells 
(p1); and 2) FACS-purification at the first passage to eliminate the few non-transduced 
cells, followed by implantation at the second passage (p2). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Study design for short-term expansion experiments. BMSC were isolated and transduced with 
a bicistronic retroviral vector co-expressing rat VEGF164 (rVEGF164) and a truncated version of rat CD8a 
(tr.rCD8a). Implantation was performed either immediately after transduction, when cells reached the 
first confluency (p1), or after FACS-purification to eliminate the few non-transduced cells, which required 
one more passage (p2). LTR = retroviral Long Terminal Repeats; ψ = packaging signal; IRES = Internal 
Ribosomal Entry Sequence. 
Grafts were explanted 8 weeks after implantation to evaluate both blood vessel growth 
and bone tissue formation. Similarly to the results described with extensively expanded 
cells, grafts generated both by p1 and p2 naïve and CD8-BMSC were vascularized by 
sparse vessels displaying characteristics of normal arterioles, with a regular smooth 
muscle coating, and only few pericyte-covered capillaries (Figure 3.4A-D). Both p1 and 
p2 VEGF-expressing BMSC, on the other hand, caused a large increase in the amount of 
pericyte-covered microvascular networks, while preserving the presence of a few 
arterioles (Figure 3.4E-F). As shown in Figure 3.4G, quantification of vessel length 
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density showed that VEGF-expressing BMSC caused a 2- to 3-fold increase in graft 
vascularization (p1 = 13.3 ± 1.1 and p2 = 13.1 ± 1.3 mm/mm2; p<0.001 for all 
comparisons) compared to naïve (p1 = 5.7 ± 0.7 and p2 = 4.7 ± 0.6 mm/mm2) and CD8-
BMSC (p1 = 6.0 ± 0.5 and p2 = 4.5 ± 0.4 mm/mm2). No difference was observed in the 
amount of vascular growth induced by either p1 or p2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 In vivo angiogenesis after short-term expansion. (A-F) Immunofluorescence staining for 
endothelium (CD31, green), pericytes (NG2, red) and smooth muscle cells (SMA, cyan) in sections of 
silicated apatite granules seeded with naïve BMSC (A-B), CD8-BMSC (C-D) or VEGF-BMSC (E-F), expanded 
for either 1 (p1) or 2 passages (p2), 8 weeks after subcutaneous implantation in nude rats. Scale bar = 50 
µm. (G) The amount of angiogenesis was quantified by measuring vessel length density, expressed as 
millimeters of vessel length per square millimeter of tissue area [mm/mm2]. Data represent mean values 
± SEM (n = 3 independent donors); **p<0.001, ***p < 0.0001. 
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Bone tissue was identified by analysis of H&E-stained sections under fluorescent light, in 
which conditions the packed parallel arrangement of collagen fibers specifically present 
in bone lamellae gives rise to autofluorescence (107). All constructs seeded with 
minimally expanded naïve- or CD8-BMSC displayed abundant formation of bone tissue, 
both with p1 and p2 cells (Figure 3.5A-D and 3.5G-J). This tissue was characterized by 
clear osteocyte lacunae, embedded in a very dense lamellar matrix, typical of mature 
bone structure (Figure 3.5M-N). However, constructs seeded with VEGF-BMSC 
contained a severely reduced amount of bone compared to the naïve or CD8-BMSC 
(Figure 3.5E-F and 3.5K-L). Qualitatively, on the other hand, the bone tissue that was 
present was similarly mature and well formed as that induced in the control conditions 
(Figure 3.5O-P). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_________________________________VEGF-EXPRESSING BMSC FOR BONE TISSUE ENGINEERING 
75 
Figure 3.5 In vivo bone formation after short-term expansion. Composite images of entire sections 8 
weeks after subcutaneous implantation in nude rats of silicated apatite granule pellets seeded with naïve 
BMSC (A-B, G-H), CD8-BMSC (C-D, I-J) or VEGF-BMSC (E-F, K-L), expanded for either 1 (p1) or 2 passages 
(p2). After staining with hematoxylin and eosin, sections were viewed under transmitted (A-F), as well as 
fluorescent light (G-L). Both duplicates of one donor are shown for each condition. Scale bar = 1 mm; n = 3 
independent donors. (M-P) High-magnification detail of dense lamellar bone matrix in a sample seeded 
with control CD8-BMSC (M-N) or VEGF-BMSC (O-P) viewed under transmitted (M, O) and fluorescent (N, 
P) light, taken from panels (C, I) and (E, K), respectively. Scale bar = 100 µm. 
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Stable engraftment of implanted BMSC 
In order to determine whether reduced bone formation in the VEGF-expressing 
constructs might be due to impaired survival of the implanted osteoprogenitors, human 
BMSC were tracked in histological sections by in situ hybridization with a probe for the 
human-specific Alu repeat sequence in nuclear DNA. Constructs seeded with naïve and 
CD8-BMSC showed a homogenous mixture of positive and negative staining within the 
bone and the surrounding soft tissue, indicating the contribution of both the implanted 
BMSC and host-derived osteoprogenitors to the new bone formation (Figure 3.6A-D). 
Human cells were also abundantly present in the VEGF-expressing constructs, both 
within the mature bone tissue and in the surrounding soft tissue (Figure 3.6E-F), 
suggesting that no impairment of BMSC engraftment had occurred compared to the 
control conditions. Interestingly, the human cells at the interface between bone and 
surrounding tissue displayed a different morphology between the VEGF-expressing and 
the control conditions. In fact, some areas of bone, formed by both naïve and CD8-BMSC, 
were covered by a single layer of flattened Alu-positive cells, similar to osteoblasts, or 
bone-lining cells (Figure 3.6A and 3.6D). In the VEGF-expressing condition, instead, the 
human cells at the bone surface often displayed many thin cytoplasmic protrusions 
stretching into the surrounding space (Figure 3.6E-F), which sometimes made contact 
with each other (arrow in Figure 3.6F), similar to the morphology of differentiated 
osteocytes. 
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Figure 3.6 In vivo cell survival. In situ hybridization for the human-specific Alu repetitive sequence (blue) 
and counterstaining with nuclear fast red (red) were performed on sections of silicated apatite granule 
pellets seeded with naïve BMSC (A-B), CD8-BMSC (C-D) or VEGF-BMSC (E-F), expanded for either 1 (p1) 
or 2 passages (p2), 8 weeks after subcutaneous implantation in nude rats. Scale bar = 100 µm; n = 3 
independent donors. 
VEGF-BMSC stimulate osteoclast recruitment 
In order to analyse bone resorption, tartrate-resistant acid phosphatase positive 
(TRAP+) osteoclastic cells were visualized. In naïve- and CD8-BMSC grafts, few TRAP+ 
cells were detected in contact or in close proximity to bone matrix (Figure 3.7A-D). 
However, constructs containing VEGF-overexpressing MSC showed a highly increased 
density of TRAP+ cells (Figure 3.7E-F). 
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Figure 3.7 Osteoclast activity. Histochemical stain for TRAP activity (red) and counterstaining with 
haematoxylin (blue) were performed on sections of silicated apatite granule pellets seeded with naïve 
BMSC (A-B), CD8-BMSC (C-D) or VEGF-BMSC (E-F), expanded for either 1 (p1) or 2 passages (p2), 8 weeks 
after subcutaneous implantation in nude rats. Scale bar = 100 µm; n = 3 independent donors. 
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3.4 DISCUSSION 
In this study we aimed at improving vascularization of tissue-engineered bone grafts by 
genetically modifying human BMSC to achieve sustained over-expression of VEGF. Our 
results confirmed that angiogenesis was significantly increased by this approach, 
leading to a 2- to 3-fold increase in vessel length density compared to naïve cells. 
Interestingly, VEGF over-expression caused not only an increase in the number of 
vessels, but also a qualitatively different composition of the vascular supply. In fact, 
grafts seeded with control cells contained mainly small arteries, which efficiently carry 
blood flow (conductance vessels), but whose thick smooth muscle coating prevents 
metabolic exchanges with the tissue. VEGF-BMSC, on the other hand, generated 
physiologically structured vascular networks, composed of a few arterioles feeding into 
a large number of pericyte-covered capillaries, whose thin walls allow efficient exchange 
of respiratory gases and nutrients. Only this second kind of vascular bed is optimal to 
sustain a high metabolic demand by growing tissue. 
The improvement in vascularization was not diminished by extensive in vitro expansion 
of the transduced BMSC up to 35 population doublings, showing that genetic 
modification conferred a stable angiogenic potential. As expected, these expanded BMSC 
lost their osteogenic potential (43, 44). However, their sustained capacity to induce 
vascularization could be useful in other applications, where effective expansion of the 
vascular bed is required, but not progenitor differentiation, such as in cell-based 
approaches for therapeutic angiogenesis in peripheral or coronary artery diseases. 
By minimizing cell expansion in order to maintain the osteogenic differentiation 
potential of BMSC, we observed a strong reduction in bone formation specifically when 
VEGF was over-expressed. In fact, CD8-BMSC, which underwent similar retroviral vector 
transduction and FACS-purification, generated bone tissue as efficiently as naïve BMSC. 
A reduced amount of bone may result from decreased bone formation, either by 
impairment of BMSC engraftment or of their osteogenic differentiation potential, or 
from increased resorption. 
In situ hybridization for the human specific Alu sequence demonstrated that VEGF-MSC 
survived similarly to naïve cells and that implanted cells could be found embedded in 
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the bone matrix in osteocyte position in all conditions. Previous results by our group 
showed that VEGF over-expression did not reduce osteoblastic differentiation of 
retrovirally transduced human BMSC in vitro (109). Furthermore, an impairment of 
BMSC osteogenicity would likely lead to abortive bone formation, with areas of dense 
matrix that fails to mineralize. However, the bone generated by VEGF-BMSC was fully 
mature and similar to that formed by control cells, only reduced in quantity. On the 
other hand, VEGF over-expression specifically caused a greatly increased density of 
TRAP-positive osteoclasts, which could be found at the surface of bone areas. Taken 
together, these results suggest that VEGF over-expression caused a reduction in the 
amount of bone tissue rather through increased resorption than by impaired cell 
engraftment or differentiation. 
Bone formation and bone homeostasis are highly connected with angiogenesis. VEGF 
upregulation is crucially required in osteochondral bone formation (6, 110). In addition, 
it has been shown that sustained VEGF over-expression promotes an increase in bone 
mass through direct stimulation of osteoblasts (81). A large number of studies found a 
positive effect of VEGF on bone regeneration (111-113), while others did not observe 
any alteration in the osteogenic capacity of rabbit BMSC over-expressing VEGF after AAV 
transduction (114). On the other hand, Schonmeyr et al. recently showed that VEGF can 
inhibit BMP2 expression by rat BMSC in an autocrine and paracrine manner (115). 
Furthermore, VEGF is a chemo-attractant for osteoclast progenitors in developing bone, 
supporting in vitro osteoclast differentiation and enhancing osteoclast survival and bone 
resorption (116, 117). In light of the sometime contradictory results reported in 
literature, the relationship between VEGF expression, vascularization, bone formation 
and bone resorption is certainly complex and likely to be context-dependent. In the 
model of ectopic implantation used in the present study, which allows the study of the 
intrinsic bone-forming capacity of the implanted cells without the influence of an 
osteogenic environment, our results suggest that VEGF over-expression impairs bone 
formation by unbalancing bone homeostasis towards disproportionate resorption. 
Further investigations, for example in osteoclast-deficient models like the op/op mouse 
(118), will be needed to conclusively prove this hypothesis. 
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It should be considered that some specific features of the model we used could affect the 
relationship between VEGF expression and osteogenicity and these could provide 
directions to explore in order to preserve the positive effect on vascularization while 
avoiding the negative effect on bone formation. These parameters are the duration of 
VEGF expression, its dose and the presence of an osteogenic environment.  
VEGF expression is required only for about 4 weeks in order to generate persistent 
vessels (93, 94) and it is possible that continued expression beyond this time, as it 
happens from the constitutive retroviral promoter that was used here, is not necessary 
for vascularization, but only provides a continued stimulation of osteoclast recruitment. 
The use of inducible promoters, which can be switched off by systemic treatment with a 
drug (119), could address this point. 
Further, the transduced BMSC we used expressed heterogeneous levels of VEGF, as a 
result of the random integration of retroviral vectors in genomic areas with different 
transcriptional activities. As normal angiogenesis can be induced over a wide range of 
VEGF levels up to a defined threshold dose (93), controlled expression at moderate 
levels might induce effective vascularization while limiting osteoclast recruitment. This 
could be achieved by using BMSC populations FACS-purified to homogeneously express 
specific VEGF levels, as we recently showed (109, 120). 
Lastly, subcutaneous implantation in an ectopic environment is a well-controlled 
experimental model. However, in physiological bone homeostasis mechanical load 
provides crucial stimulation of anabolic osteoblastic activity and, in fact, lack of muscle 
activity causes severe bone rarefaction and osteoporosis (121). Therefore, it is possible 
that implantation in an orthotopic model, where the graft is subjected to the same 
mechanical load as the natural bone, the balance between bone formation and 
resorption might be restored. 
Bone tissue engineering using bone marrow-derived stromal/stem cells is a promising 
technique for the treatment of bone defects. The lack of rapid angiogenesis, however, 
constitutes a major obstacle in the engineering of tissues of clinically relevant size. 
Therefore, several approaches to increase neovascularisation, including the supply of 
VEGF, are currently under investigation (37, 113). Our data suggest that an equilibrium 
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exists between VEGF-triggered angiogenesis, osteogenesis and bone resorption, which 
needs to be fully understood and controlled for a clinical application. 
  
4 SUMMARY & FUTURE 
PERSPECTIVES
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Bone transplantation is an absolute requirement in several pathological conditions. An 
ideal bone substitute in comparison to allografts, xenografts, synthetic materials or 
autografts would be tissue engineered by autologous progenitors. Due to their ease of 
procurement, in vitro expandability and multi-lineage differentiation potential, patient-
derived MSC are an attractive autologous cell source for regenerative medicine. 
However, any tissue which is more than 200 µm thick needs a vascular supply (75). This 
also applies to the field of tissue engineering and other regenerative medicine 
approaches, where the lack of rapid vascularization is a major obstacle, leading to 
ischemia followed by necrosis in the centre of the grafts.  
Vascular Endothelial Growth Factor (VEGF) is the master regulator of physiological 
vascular growth and is commonly used as a therapeutic transgene for the induction of 
angiogenesis. However, uncontrolled and high levels of VEGF expression can lead to 
aberrant vascular growth (93, 98). To achieve controlled expression in vivo, a high-
throughput flow cytometry-based method has previously been developed in our group. 
Linking the VEGF cDNA to a cell-surface marker (a truncated version of CD8a) in a 
bicistronic construct enabled the rapid purification of genetically-modified myoblasts 
secreting a desired VEGF level, using FACS sorting based on the intensity of CD8 
expression in each cell (100, 101). 
 
The aims of this thesis were to adapt this method to human adipose tissue- and bone 
marrow-derived mesenchymal stromal/stem cells (ASC and BMSC), and to apply these 
in a bone tissue engineering approach to increase the vascularization potential of 
osteogenic grafts. 
As MSC gradually loose their regenerative potential during in vitro expansion, we first 
optimized our genetic engineering method for MSC, so as to enable high transduction 
efficiency and FACS-purification with minimal in vitro manipulation. Chapter 2 
describes the generation of an optimized protocol allowing routine transduction 
efficiencies of > 90% of primary human ASC and BMSC already during the first plating, 
as well as flow cytometry purification of transduced cells at the time of the first passage. 
In addition we demonstrated that it was possible to FACS-purify specific sub-
populations of transduced MSC homogeneously producing desired VEGF doses. Neither 
SUMMARY & FUTURE PERSPECTIVES__________________________________________________________ 
86 
retroviral vector transduction, FACS-purification, nor the expression of the transgenes 
VEGF and CD8 impaired MSC proliferation and in vitro differentiation potential. 
Transgene expression was not lost during in vitro differentiation.  
Taken together, these data demonstrate that the technique previously developed to 
generate myoblast populations expressing specific VEGF levels was successfully adapted 
to primary human MSC derived from adipose tissue and bone marrow, thereby allowing 
in vitro manipulation to be minimized. Hence, we developed a platform, which could be 
employed for a broad range of regenerative medicine approaches. 
 
In Chapter 3, proof-of-principle was obtained by applying this platform to a bone tissue 
engineering approach. Human BMSC, transduced and rapidly FACS-purified to eliminate 
non-expressing cells, were seeded onto hydroxyapatite granules to generate non-
critically sized constructs, and were implanted subcutaneously in nude rats. In vivo 
vascularization potential was significantly increased in VEGF-expressing BMSC. 
Although VEGF expression was heterogeneous, no aberrant angiogenesis was observed. 
Indeed, orderly vascular beds were induced, with flow-conducting arterioles feeding 
into extensive capillary networks, where metabolic exchanges can take place efficiently. 
Thanks to our optimized transduction technique and rapid FACS purification, constructs 
could be generated with minimal expansion of the genetically modified BMSC for no 
more than 2 passages. In these conditions, we observed a severe reduction in the 
amount of produced bone specifically in consequence of VEGF over-expression, and not 
of retroviral transduction or FACS purification. This correlated with an increased 
recruitment of TRAP-positive osteoclasts specifically in VEGF-expressing constructs.  
 
These data suggest that VEGF over-expression might impair bone formation by 
disrupting the balance between bone formation and resorption towards excessive 
degradation. To fully understand the underlying mechanism, further experiments will be 
needed. 
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4.1 PERSPECTIVES IN BONE REPAIR 
4.1.1 IDENTIFICATION OF A SUITABLE VEGF DOSE 
Since the platform we developed allows FACS-purification of MSC expressing specific 
VEGF levels, the effect of different VEGF concentrations on in vivo bone formation can be 
studied without changing the number of VEGF-expressing cells. In this way the extent of 
the increase in angiogenesis could be controlled and the effect of microenvironmental 
VEGF dose on bone formation could be investigated. Thus such tests could reveal either 
a linear relationship between increase in VEGF expression and decrease in bone 
formation, or identify a threshold between normal and reduced bone formation due to 
specific VEGF levels. If bone formation was reduced only at VEGF levels higher than 
those needed to induce angiogenesis, increased vascularization could be obtained 
without impaired osteogenicity. Varying the number of VEGF-expression hotspots by co-
seeding naïve and VEGF-BMSC at different ratios, therefore manipulating the total VEGF 
dose, could discriminate the role of paracrine and autocrine actions of VEGF within the 
bone graft (115). 
A 3D in vitro bone organ model previously developed by a collaborator allows the 
process of bone turnover to be mimicked (122). This osteoblastic-osteoclastic-
endothelial cell co-culture system, which has been used together with non-invasive 
monitoring techniques, could be used to identify the coupling of vascularisation with the 
stage of osteoblastic differentiation of the progenitor cells and osteoclastic activity in 
vitro. 
 
4.1.2 SCALE-UP OF THE GRAFT SIZE 
Sample analysis at different time-points during the in vivo graft ossification could give 
insight into the dynamics of ongoing processes, including angiogenesis, bone formation 
and osteoclast recruitment/bone resorption, as well as their chronological relationship. 
Furthermore, an inducible expression system (119) would allow the switching-off of 
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VEGF expression at different time-points, so that long-term consequences of short-term 
VEGF-expression could be analysed. For this experimental setting, it should be taken 
into account that the process of vessel ingrowth needs to take place as rapidly as 
possible after graft implantation in order to protect the centre of the construct from 
ischemia and necrosis. Therefore, it would be fundamental to analyse the speed and 
depth of vascular invasion into constructs with a size of clinical relevance (e.g. 1cm3), as 
well as the depth of cell survival and bone formation inside those grafts, and to 
determine their dependency on the duration of VEGF expression. A minimum of 4 weeks 
of VEGF expression is required in order to induce stable persistent vessels in other 
tissues (93, 94) and it would be useful to determine whether this process may be faster 
in bone. 
 
4.1.3 EXTENSION TO AN ORTHOTOPIC AND IMMUNOCOMPETENT ANIMAL MODEL 
The experiments described here were performed in an ectopic implantation model, 
which allows the most controlled conditions to investigate the intrinsic potential of the 
implanted cells without the influence of the bone environment of orthotopic models. 
However, due to the presence of crucial stimulation by mechanical load, as well as of a 
more osteogenic and inflammatory environment, the implantation of the same grafts 
directly into the bone defect might favour osteoblastic differentiation and change the 
balance in bone homeostasis, possibly restoring bone formation (110, 123, 124). 
An additional element that has to be noted is the use of a nude rat model, which lacks T-
lymphocytes and therefore has a suppressed immune system, in order to avoid rejection 
of the human cells. As T-lymphocytes regulate osteoclastogenesis and recruit 
osteoblasts, this might have relevant consequences (123). On the other hand, it has been 
shown that several immunological surface antigens important for B-cell and T-cell 
recognition, including MHC-II, CD40, CD40L, CD80 and CD86, are not expressed on the 
surface of human MSC and that they have immunosuppressive actions (41). Therefore, 
the use of a xenogenic immunocompetent animal model would be an option to test 
human cells, even though current literature presents controversial results (125). Using 
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autologous cells and species-specific transgenes in an immunocompetent animal model, 
however, would come closest to the setting of a potential clinical application.  
 
Based on these results, some of the questions mentioned above are being addressed in a 
recently initiated project in our group, aimed at increasing vascularization and bone 
formation in critical-size bone grafts in an ectopic rabbit model by syngenic VEGF-
expressing autologous BMSC. To further stimulate vascular growth, bone tissue 
engineering using MSC overexpressing heterogenous VEGF-levels and flap pre-
fabrication were combined by wrapping the constructs in the highly vascularised 
panniculus carnosus muscle. Kinetic studies on construct perfusion 1, 4 and 8 weeks 
after implantation indicate that VEGF expression accelerated perfusion of critical-size 
bone grafts and reduced the size of the ischemic central core. Complete vessel 
quantification and histological analysis for bone formation in the explanted grafts are 
currently ongoing. 
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4.2 PERSPECTIVES IN OTHER FIELDS OF REGENERATIVE MEDICINE 
The method described in chapter 2 provides a general platform to generate populations 
of genetically modified MSC, expressing specific levels of a therapeutic transgene, 
already at the time of the first passage. Therefore, it has the potential to be applied in 
other fields of regenerative medicine, beyond bone tissue engineering. Here we briefly 
describe two recently initiated projects, based on the results described in this thesis, 
which aim at either promoting or inhibiting angiogenesis in order to improve cardiac 
function after myocardial infarction, or cartilage tissue formation, respectively. 
 
In order to investigate cell-based delivery of controlled VEGF levels for safe and robust 
angiogenesis in the heart, human adipose tissue-derived stem cells (ASC) were 
transduced with the same retroviral vector construct described in Chapters 2 and 3 
VEGF-expressing progenitors were then FACS-purified to generate populations 
producing either a specific (SPEC) or heterogeneous (ALL) VEGF levels. In a first trial, 
healthy nude rats underwent intramyocardial cell injection. Histological analysis 4 
weeks post implantation revealed that both VEGF-producing groups induced robust 
angiogenesis, with a 2-3-fold increase in vessel density compared to control cells, 
despite very limited stable engraftment of injected cells. Nevertheless, heterogeneous 
VEGF levels caused numerous angioma-like structures, while the homogeneous 
expression of a specific VEGF dose generated only normal and stable angiogenesis. 
Following those proof-of-principle experiments, the study was extended to a nude rat 
model of myocardial infarction. A control group which received only PBS was added. 
After 4 weeks, the left ventricular ejection fraction (EF) was preserved by the treatment 
with SPEC VEGF cells (EF=+1.1%), but significantly worsened by treatment with ALL 
VEGF cells (-13.2%), control cells (-6.4%) and PBS injection (-8.3%). Vessel density was 
increased by 2- to 3-fold with both VEGF-producing cell groups. However, ALL VEGF 
cells caused the development of numerous aberrant angioma-like structures, while they 
were completely prevented by SPEC VEGF cells, which induced only normal and stable 
angiogenesis also in ischemic myocardium. 
__________________________________________________________SUMMARY & FUTURE PERSPECTIVES 
91 
These results show that controlled VEGF delivery by FACS-purified ASC is effective to 
reliably induce only normal vascular growth and functional improvement in ischemic 
myocardium, opening up the exciting possibility of its clinical application to achieve safe 
and therapeutic angiogenesis to treat cardiac ischemia. 
 
Unlike in bone and cardiac tissue, VEGF expression is suppressed during hyaline 
cartilage formation and maintenance, and vascular invasion actually causes destruction 
of the cartilagineous tissue. Therefore, in order to favour chondrogenic differentiation of 
mesenchymal progenitors in vivo, we hypothesized that it could be beneficial to block 
endogenous VEGF signalling with a soluble form of VEGF receptor-2 (sFlk-1). Human 
chondrocytes and BMSC, which are promising cell sources for cartilage regeneration, 
were transduced to express sFlk-1 using the protocol described in chapter 2. 
Chondrogenic differentiation capacity was investigated in a pellet culture system in 
vitro. In vivo chondrogenesis and the control of angiogenesis were analyzed after 
seeding on collagen-based scaffolds and ectopic implantation in nude mice.  
In vitro, sFlk-1 appeared to have no effect on chondrogenic differentiation of either 
chondrocytes or BMSC. In vivo, blood vessel ingrowth was significantly reduced in the 
engineered tissues formed by sFlk-1-expressing cells, compared to naïve and control 
cells tranduced with an empty vector. Blocking of angiogenesis significantly enhanced 
chondrogenesis in vivo by human chondrocytes, but was found to be actually critical to 
allow any cartilage formation by BMSC in vivo. In fact, no chondrogenesis was observed 
in any condition except in the sFlk-1-expressing constructs. 
 
In conclusion, this work proposes a technological platform to control vascularization in 
several tissue engineering and regenerative medicine approaches, either to stimulate or 
to inhibit angiogenesis. The thesis also provides an exemplification of this approach in 
the context of bone repair and discusses further extensions in different therapeutic 
areas. 
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